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ABSTRACT 
Estrogens and progestins used in conventional menopausal hormone therapy (HT) are 
associated with increased breast cancer risk. A diverse range of estrogens and progestins are 
available that mediate their effects primarily by binding to the estrogen receptor (ER) and 
progesterone receptor (PR), respectively. Although the link to breast cancer risk has not been 
shown for all estrogens and progestins, many women have turned to custom-compounded 
bioidentical hormone therapy (bHT) as it is claimed to not increase breast cancer risk. 
However, scientific evidence to support this claim is lacking. Estrogens and ERα are 
considered the main etiological factors driving breast cancer, while both ERα and the PR are 
required for progestin (medroxyprogesterone acetate (MPA)) effects on breast cancer cell 
proliferation. In this thesis, we investigated the activities of estrogens and progestins used in 
menopausal hormone therapies via the individual ER subtypes, and the role of ERα/PR 
crosstalk in mediating progestin-induced effects on gene expression, breast cancer cell 
proliferation and anchorage-independent growth. In the first part of the study, competitive 
whole cell bindings assays showed that bioidentical estradiol (bE2) and estriol (bE3) displayed 
similar binding affinities to the commercially available (natural) estradiol (E2) and estriol (E3) 
standards, while synthetic ethinylestradiol (EE) had a higher affinity for ERα, and natural E1 a 
lower affinity for ERβ. Furthermore, the bioidentical estrogens mimicked their respective 
natural estrogens and synthetic EE on transactivation and transrepression of gene expression, 
proliferation and anchorage-independent growth of the estrogen-sensitive MCF-7 BUS human 
breast cancer cell line. These assays showed that E3 and estrone (E1) are efficacious estrogens 
that do not antagonize E2. In the second part of this study, the estrogenic activities of selected 
progestins from different generations, MPA, norethisterone acetate (NET-A), levonorgestrel 
(LNG), gestodene (GES), nestorone (NES), nomegestrol acetate (NoMAC) and drospirenone 
(DRSP), were characterized relative to each other and natural progesterone (P4). Competitive 
binding assays revealed that only NET-A, LNG and GES could bind to ERα, while no progestin 
bound ERβ. Both transactivation and transrepression transcriptional assays showed that NET-
A, LNG and GES display estrogenic activity. In the third part of the study, the role of PR/ERα 
crosstalk in mediating the effects of MPA, NET and DRSP, relative to P4, on breast cancer cell 
proliferation, anchorage-independent growth and the expression of the ER-regulated trefoil 
factor 1 (pS2) and cathepsin D (CTSD) genes was investigated. All progestins could promote 
proliferation and anchorage-independent growth of MCF-7 BUS breast cancer cells to the same 
extent as P4 and E2 via a mechanism requiring both the PR and ERα, but DRSP was the least, 
and MPA the most potent for proliferation. Quantitative real-time RT-PCR (qPCR), chromatin 
immunoprecipitation (ChIP) and re-ChIP assays showed that only MPA and NET increased 
the expression of the pS2 and/or CTSD genes via a mechanism requiring co-recruitment of the 
PR and ERα to the promoter regions of these genes. In contrast, P4, MPA, NET and DRSP all 
caused recruitment of the PR/ERα complex to the PR-regulated oncogenes cyclin D1 and MYC. 
Taken together, the findings of this study suggest that there is no advantage in choosing bHT 
above conventional HT, and that while it is unlikely that the progestins used in this study will 
exert biological effects via ERα or ERβ in vivo, some progestins may increase breast cancer 
risk via a mechanism involving interplay between the PR and ERα. 
Stellenbosch University  https://scholar.sun.ac.za
  
iv 
 
OPSOMMING 
Die gebruik van estrogene en progestiene in konvensionele menopousale hormoonterapie (HT) 
word geassosieër met ‘n toename in die risiko van borskanker. ‘n Verskeidenheid van estrogene 
en progestiene, wat hul effekte hoofsaaklik uitvoer deur die estrogeenreseptor (ER) en 
progesteroonreseptor (PR) onderskeidelik, is beskikbaar. Alhoewel die toenemende risiko van 
borskanker nog nie vir al die estrogene en progestiene getoon is nie, maak baie vrouens eerder 
gebruik van persoonlike saamgestelde bioidentiese hormoonterapie (bHT) aangesien daar beweer 
word dat dit nie borskanker risiko verhoog nie. Wetenskaplike bewyse om hierdie bewering te 
ondersteun is egter nie beskikbaar nie. Estrogene en ERα word beskou as die hoof etiologiese 
faktore wat borskanker dryf, terwyl beide ERα en die PR vir die effekte van progestien 
(medroksieprogesteroonasetaat (MPA)) op borskankerselproliferasie benodig word. In hierdie 
tesis, het ons die aktiwiteite van estrogene en progestiene, gebruik in menopousale 
hormoonterapies, deur die individuele ER subtipes ondersoek, asook die rol van ERα/PR 
wisselwerking in progestien-geïnduseerde geenuitdrukking, borskankerselproliferasie en 
geankerde-onafhanklike groei. In die eerste deel van die studie het kompeterende heelsel 
bindingstoetse getoon dat bioidentiese estradiool (bE2) en estriool (bE3) dieselfde 
bindingsaffiniteite het as die komersieël beskikbare (natuurlike) estradiool (E2) en estriool (E3) 
standaarde, terwyl sintetiese etinielestradiool (EE) ‘n hoër affiniteit vir ERα, en natuurlike estroon 
(E1) ‘n laer affiniteit vir ERβ het. Verder, boots die bioidentiese estrogene hul onderskeidelike 
natuurlike estrogene en sintetiese EE na in terme van transaktivering en transonderdrukking van 
geenuitdrukking, proliferasie en geankerde-onafhanklike groei van die estrogeen-sensitiewe MCF-
7 BUS menslike borskankersellyn. Hierdie toetse het getoon dat E3 and estroon (E1) doeltreffende 
estrogene is wat nie E2 antagoniseer nie. In die tweede deel van die studie was die estrogeniese 
aktiwiteite van geselekteerde progestiene van verskillende generasies, MPA, noretisteroonasetaat 
(NET-A), levonorgestrel (LNG), gestodeen (GES), nestoroon (NES), nomegestroolasetaat 
(NoMAC) en drospirenoon (DRSP), relatief tot mekaar en natuurlike progesteroon (P4), 
gekarakteriseer. Kompeterende bindingstoetse het aan die lig gebring dat slegs NET-A, LNG en 
GES aan ERα kon bind, terwyl geen van die progestiene ERβ bind nie. Beide transaktiverings- en 
transonderdrukkingstoetse het gewys dat NET-A, LNG en GES estrogeniese aktiwiteite toon. In 
die derde deel van die studie was die rol wat PR/ERα wisselwerking speel in die uitvoering van 
MPA, NET en DRSP, relatief tot P4, op borskankerselproliferasie, geankerde-onafhanklike groei 
en die uitdrukking van die ER-gereguleerde trefoiël faktor 1 (pS2) en katepsien D (CTSD) gene 
ondersoek. Al die progestiene kon proliferasie en geankerde-onafhanklike groei van die MCF-7 
BUS borskankerselle tot dieselfde mate as P4 en E2 bevorder deur ‘n meganisme wat beide die PR 
en ERα benodig, maar DRSP was die minste, en MPA die meeste potent vir proliferasie. 
Kwantitatiewe intydse RT-PKR, kromatienimmunopresipitasie (ChIP) en her-ChIP toetse het 
getoon dat slegs MPA en NET die uitdrukking van die pS2 en/of CTSD gene verhoog deur ‘n 
meganisme wat die mede-werwing van die PR en ERα tot die promotor areas van hierdie gene 
vereis. In teendeel, P4, MPA, NET en DRSP het almal die werwing van die PR/ERα kompleks tot 
die PR-gereguleerde onkogene siklien D1 (CCND1) en MYC veroorsaak. In samevatting, die 
bevindinge van hierdie studie stel voor dat daar geen voordeel is om bHT te kies bo konvensionele 
HT nie, en alhoewel dit onwaarskynlik is dat die progestiene wat gebruik is in hierdie studie 
biologiese effekte deur ERα of ERβ sal uitvoer in vivo, mag sommige progestiene wel borskanker 
risiko verhoog deur ‘n meganisme wat wisselwerking tussen die PR en ERα behels. 
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THESIS OUTLINE 
This thesis consists of five chapters. Chapters 1 and 4 are written up in manuscript format and 
will soon be submitted for publication. Chapters 2 and 3 consist of recently published research 
articles and supplementary data. Chapter 5 is a general discussion and conclusion chapter. 
References are presented at the end of each individual chapter. 
1. Chapter 1: Hormone Therapy and Breast Cancer: Emerging Steroid Receptor 
Mechanisms. This chapter is a detailed literature review discussing menopausal 
hormone therapy (HT) and its association with increased breast cancer risk, with 
specific focus on different types of HT, the role of steroid receptors in mediating 
increased breast cancer risk, and the influence of crosstalk between steroid receptors. 
This review was written by the candidate, with Dr. Renate Louw-du Toit and Prof. 
Donita Africander providing intellectual input, as well as proofreading and editing of 
the manuscript. 
2. Chapter 2: A comparative characterization of estrogens used in hormone therapy 
via estrogen receptor (ER)-α and -β. This chapter is composed of an article published 
in The Journal of Steroid Biochemistry and Molecular Biology comparing the effects 
of estrogens used in conventional and bioidentical HT on gene regulation, as well as 
proliferation and anchorage-independent growth of the MCF-7 BUS human breast 
cancer cell line. All experiments and data analysis were performed by the candidate. 
3. Chapter 3: Comparing the androgenic and estrogenic properties of progestins 
used in contraception and hormone therapy. This chapter is composed of an article 
published in Biochemical and Biophysical Research Communications investigating the 
off-target activities of selected progestins via the estrogen- and androgen receptors. The 
candidate performed and analyzed all experiments pertaining to the estrogen receptor 
experiments, while contributing equally to Dr. Renate Louw-du Toit in terms of the 
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writing, editing and intellectual input of the publication. The candidate thus shares first 
authorship with Dr. Renate Louw-du Toit. 
4. Chapter 4: Upregulation of estrogen receptor-regulated genes by first generation 
progestins requires both the progesterone receptor and estrogen receptor alpha. 
This chapter contains the results of a study investigating the effects and potential 
underlying mechanism(s) of selected progestins used in HT on the proliferation and 
anchorage-independent growth of the MCF-7 BUS human breast cancer cell line, as 
well as the expression of ER-regulated target genes. All experiments and data analysis 
were performed by the candidate. 
5. Chapter 5: Conclusion and Future Studies. This chapter discusses the overall results 
of the study and draws conclusions based on the new findings presented in Chapters 2-
4, together with the existing information of estrogens and progestins used in HT at the 
physiological and cellular level. This chapter also provides perspectives for future 
studies. 
 
Two appendices are presented at the back of the thesis. Appendix A contains additional 
experimental data, while Appendix B contains other outputs of the PhD study as well as other 
publications to which the candidate contributed. 
Consistent with manuscript format, the collective term “we” and “our” is often used in this 
thesis. However, all the experimental work was performed by the candidate, with the exception 
of the experimental work for the AR conducted by Dr. Renate Louw-du Toit as disclosed at 
the beginning of Chapter 3. As each chapter of the thesis is presented as an individual 
publication, some overlap is found between the chapters. 
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Versus Late Intervention Trial; EMAS, European Menopause and Andropause Society; EPHT, 
Estonian Postmenopausal Hormone Therapy; ER, estrogen receptor; ESPRIT, Estrogen in the 
Prevention of Re-infarction trial; GES, gestodene; GPER, G-protein estrogen receptor; GPR30, 
G protein-coupled receptor 30; GR, glucocorticoid receptor; HERS, Heart and 
Estrogen/Progestin Replacement Study; IMS, International Menopause Society; HT, hormone 
therapy; KEEPS, Kronos Early Estrogen Prevention Study; LNG, levonorgestrel; MPA, 
medroxyprogesterone acetate; MR, mineralocorticoid receptor; MWS, Million Women Study; 
NAMS, North American Menopause Society; NES, nestorone; NET-A, norethisterone acetate; 
NGM, norgestimate; NoMAC, nomegestrol acetate; P4, progesterone; PEPI, Postmenopausal 
Estrogen and Progestin Intervention; PR, progesterone receptor; SERMS, selective estrogen 
receptor modulators; SHBG, sex hormone-binding globulin; T, testosterone; WHI, Women’s 
Health Initiative; WISDOM, The Women's international study of long-duration oestrogen after 
menopause  
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Abstract 
Hormone therapy (HT) has been used by millions of women for several decades to relieve the 
symptoms of menopause. Although effective at relieving menopausal symptoms, HT has been 
associated with several severe side-effects such as coronary heart disease, stroke and increased 
invasive breast cancer risk. Interestingly, estrogen-progestin HT combinations have been 
associated with a greater breast cancer risk than estrogen only HT regimens. The highly 
publicized side-effects of HT have caused many women to seek alternatives to conventional 
HT, including the controversial custom-compounded bioidentical hormone therapy (bHT), 
suggested to not increase breast cancer risk. Considering that breast cancer is the most prevalent 
cancer among women worldwide, understanding the mechanism behind the increased breast 
cancer risk associated with HT is a priority. Although estrogens and the estrogen receptor were 
historically considered the principal factors promoting breast cancer development and 
progression, evidence has highlighted a role for other members of the steroid receptor family 
including the progesterone, androgen, glucocorticoid and mineralocorticoid receptors in breast 
cancer pathogenesis. Moreover, recent studies have revealed a role for crosstalk between 
steroid receptors and their signaling pathways in breast cancer. The implications of this 
crosstalk on the breast cancer risk associated with HT therefore requires investigation, 
especially since interactions between many different steroid receptors have been reported. In 
this review, we discuss examples of HT used for the relief of menopausal symptoms, 
highlighting the distinction between conventional HT and custom-compounded bHT. We also 
summarize the current knowledge regarding the role of steroid receptors in mediating the 
carcinogenic effects of hormones used in HT, with special emphasis on the influence of the 
interplay or crosstalk between steroid receptors. Unraveling the intertwined nature of steroid 
hormone receptor signaling pathways in breast cancer biology may reveal novel prevention or 
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treatment options and lead to the development of HT that does not cause increased breast cancer 
risk.   
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1. Introduction 
Menopause is characterized by the natural, age-related decrease in endogenous estrogen 
production in women, often leading to a variety of symptoms such as hot flashes, mood swings 
and night sweats [1–3]. Conventional United States Food and Drug Administration (FDA)-
approved hormone therapy (HT) has been used for decades to alleviate these symptoms and is 
typically administered as estrogen alone to hysterectomized women, or an estrogen-progestin 
combination to women with a uterus [1–4]. While the estrogen component alleviates the 
symptoms of menopause by compensating for reduced endogenous estrogen production, the 
progestin constituent counteracts the proliferative effects of estrogens on the uterine epithelium 
[1]. Even though HT is effective in relieving menopausal symptoms, some HT regimens have 
been associated with several severe side-effects including coronary heart disease, stroke and 
increased invasive breast cancer risk [4–9]. Considering that breast cancer is the most prevalent 
cancer among women in developed counties [10–12], the association between HT and 
increased breast cancer risk is of significant concern.  
The increased breast cancer risk linked to conventional HT has caused many women and 
medical professionals to seek various safer HT options, including the use of ‘natural’ 
alternatives such as custom-compounded bioidentical HT (bHT) [13,14]. Notably, some 
bioidentical hormones such as bioidentical estradiol (bE2) or bioidentical progesterone (bP4) 
are available in FDA-approved standard dose prescription medications [15,16]. However, 
unlike these FDA-approved HT products containing bioidentical hormones, custom-
compounded bHT formulations are administered in personalized doses and are typically 
composed of a mixture of up to six hormones [17,18]. Uncertainty remains regarding the 
efficacy and safety of custom-compounded bHT, especially pertaining to these multiple-
hormone combination therapies [17,18]. Although proponents of bHT claim that there is in fact 
evidence to support the efficacy and safety of custom-compounded bHT in terms of breast 
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cancer risk [19,20], these claims are unsubstantiated due to the lack of large-scale, double-
blinded clinical trials investigating custom-compounded multiple-hormone bHT regimens at 
various doses. 
Estrogen only and estrogen-progestin combination conventional HT have both been implicated 
in increased breast cancer risk, however, evidence suggests that the estrogen-progestin 
combination therapies are associated with a greater risk than the estrogen alone therapies 
[5,6,9,21,22]. Estrogens predominantly mediate their effects by binding to the estrogen 
receptor (ER), while progestins are synthetic progestogens (progesterone receptor (PR) 
ligands) that were designed to mimic the activity of the natural progestogen, progesterone (P4), 
by binding to the PR. However, it is known that some progestins can bind to the glucocorticoid 
receptor (GR), mineralocorticoid receptor (MR) and androgen receptor (AR) ([23–25], 
reviewed in [26–28]). Whether progestins bind to the ER is contradictory. While some studies 
suggest that medroxyprogesterone acetate (MPA) and norethisterone (NET) can bind to the ER 
and elicit estrogenic activity, others suggest that they do not (reviewed in [28]). Furthermore, 
it has been suggested that it is the progestin metabolites rather than the parent progestin itself 
that bind to the ER [29,30]. Although several studies have investigated effects of progestins via 
steroid receptors other than the PR [27,31], these studies seldom directly compare different 
progestins in parallel and often use cell lines that endogenously express other steroid receptors 
to which progestins can bind, which may result in inaccurate results in terms of binding 
affinities, as well as potencies and efficacies for gene expression. It is thus essential that the 
pharmacological properties of the progestins for each individual steroid receptor are 
determined in parallel in a model system expressing only the receptor of interest, as has been 
done for MPA and NET via the human GR, MR and AR [23–25]. 
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The role of the ER, which exist as two subtypes transcribed from two distinct genes [32–34], 
ERα and ERβ [35], has been extensively studied in breast cancer cell biology. Traditionally, 
estrogens and ERα were thought to be the main etiological factors contributing to breast cancer 
pathogenesis, while the PR was considered only as an indicator of a functional ER in breast 
cancer tumors, implying that the cancer should be sensitive to endocrine targeting therapies 
[36–38]. However, recent studies have highlighted novel roles for the PR in breast cancer cell 
biology [39–42]. Two main PR isoforms have been identified, PR-A and PR-B [43], and have 
been shown to elicit differential effects [44–51]. A recent study has shown that unliganded PR-
B enhances the effects of ER agonists on ERα-mediated breast cancer cell proliferation and 
gene expression by forming a complex with ERα [52]. Moreover, it has been shown that when 
PR-B is activated by P4 or the synthetic PR agonist, promegestone (R5020), it is recruited to 
the ERα complex and redirects the complex to different target genes such that the new gene 
expression profile is associated with a good clinical outcome [40]. ERα has also been shown 
to be required for PR-mediated increased cell proliferation and the expression of PR-regulated 
genes induced by the progestin MPA [41]. Interestingly, the presence and critical roles of other 
steroid receptors in breast cancer cell biology has been highlighted in recent studies. For 
example, the AR is expressed in 90% of breast cancer tumors (reviewed in [53]) and its 
expression is associated with either a good or poor prognosis depending on the absence or 
presence of the ER [54]. Similarly, GR expression has been associated with a good outcome in 
ER-positive cancers, but is associated with a poor outcome in ER-negative cancers [55,56]. 
Steroid receptor signaling pathways have often been studied in isolation, however, it is 
becoming increasingly clear that these pathways are intertwined. The ability of some steroid 
hormones, such as progestins, to activate multiple steroid receptors, coupled with the 
complexity of steroid receptor crosstalk, highlights the intricacies of the mechanisms through 
which hormones used in HT may increase breast cancer risk and promote breast cancer 
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pathogenesis. In order to elucidate the involvement of steroid receptor crosstalk in the 
mechanism behind HT and increased breast cancer risk, additional comparative studies of 
hormones used in HT are need at the cellular level. The aim of this review is to highlight 
differences between conventional HT and custom-compounded bHT and to discuss known 
mechanisms behind conventional HT-induced increased breast cancer risk with an emphasis 
on the role of steroid receptor crosstalk. 
 
2. Menopause and hormone therapy  
Menopausal transition typically occurs in women between the ages of 40 and 60 years and is 
characterized by the natural age-related loss of ovarian follicular function leading to decreasing 
endogenous estrogen, P4 and testosterone (T) levels (Table 1) [1,2]. There are three main 
endogenous human estrogens, namely E2, estriol (E3) and estrone (E1), the latter being the most 
abundant circulating estrogen in post-menopausal women (Table 1). However, E1 is not present 
in sufficient levels to prevent the symptoms of menopause, such as amenorrhea, hot flushes, 
night sweats, vaginal atrophy and mood fluctuations [1,2,20]. HT was first administered in the 
1930s to alleviate these menopausal symptoms [4], but also to prevent the medical implications 
of decreased endogenous estrogen levels including osteoporosis, Alzheimer’s disease, arthritis, 
coronary heart disease and cataract formation [1,2]. Today, a large variety of HT regimens are 
commercially available and can be broadly divided into conventional HT and custom-
compounded bHT. 
Table 1. Serum estradiol (E2), estriol (E3), estrone (E1), progesterone (P4) and testosterone 
(T) levels in pre- and post-menopausal women [57–75]. 
 
 E2 E3 E1 P4 T 
Pre-menopausal (pg/ml) 7 - 400 8 - 2 408 12 - 144 566 - 15 700 217 - 2 200 
Post-menopausal (pg/ml) 1 - 20 < 10 7 - 44 39 - 700 461 - 1050 
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2.1. Conventional hormone therapy 
The term conventional HT can be interpreted in many ways due to the fast-evolving nature of 
drug discovery, however, for the purposes of this review, conventional HT will refer to all 
FDA-approved HT regimens available in the United States of America (USA). Conventional 
HT regimens are marketed under different brand names and contain either natural, synthetic or 
bioidentical hormones which are available in standardized doses and various routes of 
administration. Depending on the HT, it can be administered either orally, subcutaneously, 
transdermally, intravaginally or by intramuscular injection [1,3].  
HT preparations are composed of various hormones that can be ascribed to a specific class. 
Class A steroids include hormones that are naturally occurring and administered without 
chemical modification. For example, conjugated equine estrogens (CEE) containing estrogens 
such as equilin are extracted from pregnant mare’s urine [76,77]. Although, these steroids are 
naturally occurring, they are not endogenous to the human body [76,77]. Class B steroids are 
often referred to as natural or bioidentical, however these hormones are chemically synthesized 
from a natural steroidal precursor using numerous chemical reactions [78] and are thus semi-
synthetic [58,77,79,80]. Class C steroids differ from class B steroids in that they are 
synthesized from non-steroidal, rather than steroidal, precursors in a process called total 
synthesis [77]. The shortcoming of class B and C steroids is that various isomers are produced 
during the synthesis process, with only one of these isomers structurally identical to the 
endogenous human hormone [14,77]. For example, during total E1 synthesis, eight racemates 
(differentiated by the left- and right-handed enantiomers of a chiral molecule) are produced, 
resulting in 16 isomers of which only one is structurally and biochemically identical to 
endogenous human E1 [77]. The remaining isomers have different structures and varying 
degrees of estrogenicity, while some are even completely inactive [77]. Lastly, class D steroids 
are man-made steroidal compounds synthesized either from the same steroidal plant precursors 
Stellenbosch University  https://scholar.sun.ac.za
 10 
 
as class B hormones by semi-synthesis, or from nonsteroidal starting material by total synthesis 
[77]. Examples of class D steroids include estrogens such as estropipate, esterified estrogens 
and ethinylestradiol (EE), as well as the progestins MPA, NET acetate (NET-A), levonorgestrel 
(LNG) and norgestimate (NGM).  
Premarin is an example of a HT containing natural CEE that has been effective in relieving 
menopausal symptoms from as early as 1942 [4]. Various other estrogens have subsequently 
become available for use in conventional HT and include synthetic, rather than natural CEE, 
bE2, as well as the less commonly used esterified estrogens, estropipate and synthetic E2 
derivatives including EE, E2 valerate, E2 cypionate and E2 acetate (Table 2). Although estrogen 
only HT is effective at relieving menopausal symptoms, studies in the 1960’s reported 
increased incidence of endometrial cancer in Premarin users [4,81,82]. This necessitated the 
addition of a progestin to CEE regimens for women with a uterus, to prevent estrogen-induced 
endometrial hyperplasia [4]. Progestins are used to mimic the activity of P4, but have a longer 
half-life and a higher bioavailability [31,77]. Products such as Prempro (CEE-MPA) and 
Provera (MPA) (Table 3) thus became commercially available as early as 1965 [83]. Although 
Provera is produced as a progestin-only HT, it is administered in combination with an estrogen 
only HT [84]. Various generations of progestins have subsequently been developed, derived 
either from P4, T or the MR antagonist spironolactone, where each new generation is designed 
to have a greater affinity for the PR and elicit biological effects more like P4 than progestins 
from the earlier generations [28,85,86]. Note that P4-derivatives can be either 17-hydroxy-P4 
derivatives or 19-Nor-P4 derivatives. 
Progestins currently used in FDA-approved HT include the first-generation progestins MPA 
and NET-A, second-generation progestin LNG, third-generation progestin NGM and the 
fourth-generation progestin, drospirenone (DRSP) (Fig.1). Not all progestins are used 
clinically in the USA. For example, nomegestrol acetate (NoMAC) is used in HT in Europe 
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[22], but not in the USA. Interestingly, NoMAC and progestins such as nestorone (NES), and 
gestodene (GES) (Fig. 1) are currently being investigated in clinical trials for use in 
contraception in the USA [86,87]. 
 
Figure 1. Structures of various first (1st)-, second (2nd)-, third (3rd)- and fourth (4th)-generation 
progestins. Progestins structurally related to (A) progesterone (P4) include the first-generation, 17-
hydroxy-P4 derivative, medroxyprogesterone acetate (MPA) and the fourth-generation, 19-Nor-P4 
derivatives, nomegestrol acetate (NoMAC) and nestorone (NES), while progestins structurally 
related to (B) testosterone (T) include the first-generation progestin, norethisterone acetate (NET-
A), the second-generation progestin, levonorgestrel (LNG), and the third-generation progestins, 
gestodene (GES) and norgestimate (NGM). (C) The fourth-generation progestin drospirenone 
(DRSP) is currently the only progestin structurally related to spironolactone, a MR antagonist. 
Structures were obtained from Pubchem (https://pubchem.ncbi.nlm.nih.gov). 
 
The continual evolution of HT is thought to be aimed at designing estrogens and progestogens 
that effectively manage menopausal symptoms without eliciting unwanted side-effects. More 
C 
Progesterone Derivatives Testosterone Derivatives 
P4 T 
MPA (1st)  
NES (4th)  
NoMAC (4th)  NET-A (1st)  LNG (2nd)  
GES (3rd)  DRSP (4th)  
Spironolactone 
Derivative 
A B 
NGM (3rd)  
17-hydroxy-P4 derivative  19-Nor-P4 derivatives  
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recent advances in HT evolution saw the introduction of bioidentical hormones. FDA-approved 
bE2 only products [88,89] are available in standardized doses in products such as Alora, 
Vivelle-Dot, Divigel, Elestrin, Estrogel and Estrace (Table 2), or in combination with 
progestins such as NET-A (Activella, Mimvey, Combipatch), DRSP (Angeliq), NGM (Prefest) 
or LNG (Climara Pro) (Table 3). Interestingly, although FDA-approved bP4 is available as 
Prometrium in the form of a cream or as a pill that is administered together with an estrogen 
only HT, there are no standardized FDA-approved bE2-bP4 combination formulations 
available. Notably, bP4 is administered in a micronized form, referring to the fact that the 
particle size has been decreased to generate finer powders that are more readily absorbed, and 
thus have an increased bioavailability to compensate for the short half-life of the natural 
hormone [19,90]. However, both oral and transdermal micronized bP4 formulations are 
dissolved in peanut oil and consequently cannot be used by women with nut allergies [91–95]. 
Another alternative HT regimen involves the use of SERMs (selective estrogen receptor 
modulators). SERMs elicit tissue-selective estrogenic activity by acting as ER agonists in bone 
tissue, increasing bone mineral density and bone strength, but as ER antagonists in the breast 
and endometrium to prevent breast and endometrial cancer [96]. FDA-approval was recently 
granted to Duavee, a CEE-SERM (bazedoxifene) combination to be used for the relief of 
menopausal symptoms as well as to prevent post-menopausal osteoporosis [96–100].  
Estrogen only and progestogen-containing FDA-approved HT products are outlined in Tables 
2 and 3, respectively. These tables indicate the routes of administration and dose range of the 
various HTs and, where available, the resulting serum concentrations of E2, E1, EE, the 
progestogens or bazedoxifene. Although these conventional HT regimens are still widely used 
and have proved efficient at relieving menopausal symptoms [101], the reported side-effects 
associated with conventional HT have caused many women to seek alternate menopausal relief 
in the form of custom-compounded bHT [77]. 
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Table 2. FDA-approved estrogen only HT products [102–104] (a-ad). 
Composition Products (™) 
Route of  
Administration 
Administered 
Doses (min - max) (mg) 
Serum E2 
(pg/ml) 
Serum E1 
(pg/ml) 
Natural CEE Premarin 
Pill 
Vaginal Cream 
0.3 - 1.25 
0.625* 
NA  
NA 
87 - 4 500 
42 - 600 
Synthetic CEE Cenestin, Enjuvia Pill 0.3 -1.25 NA 20 - 85 
bE2 
Alora, Climara, Esclim, 
Estraderm, Estradot, Menostar, 
Minivelle, Vivelle-Dot 
Patch 0.025 - 0.1 6 - 174 9 - 65 
Divigel, Elestrin, Estrogel Topical Gel 0.025 - 2.0* 9 - 67 33 - 66 
Estrace, Gynodiol Pill  0.5 - 2.0 203 - 355 ND
 
Estrace Vaginal Cream  0.1* ND ND
 
Estrasorb Topical Cream 2.5* 59 - 70 ND 
Estring Vaginal Insert 2.0 8 - 63 44 - 66 
Evamist Topical Spray 1.53# 11 - 57 NA 
Vagifem Vaginal Tablet 0.01 - 0.025 6 -21 17 - 28 
E2 valerate Delestrogen IM Injection 10 - 40 ND
 ND 
E2 cypionate Depo-Estradiol IM Injection 1.0 - 5.0 ND ND 
E2 acetate 
Femring Vaginal Ring 0.05 - 0.10 41 - 76 36 - 46
Femtrace Pill 0.45 - 1.8 57 - 177 155 - 680
Esterified estrogen 
Menest Pill 0.3 - 2.5 ND ND 
Estragyn Vaginal Cream 1.0* ND ND 
Estropipate Ogen 
Pill 0.75 - 3.0 ND ND 
Vaginal Cream 1.5* ND ND  
* - mg hormone per g cream # - mg hormone per single HT spray         NA - not applicable as these HT products do not contain the relevant hormone 
ND - serum concentrations have not been reported      a-ad - package inserts can be found at the end of the reference list      IM - intramuscular injection 
E
2
 d
er
iv
a
ti
v
es
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Table 3. FDA-approved progestogen or SERM-containing HT products [105,106] (ae-ao). 
Composition Products 
Route of 
Administration 
Administered 
Doses (mg) 
Serum E2 
(pg/ml) 
Serum E1 
(pg/ml) 
Serum Progestogen 
(pg/ml) 
Progestogen only 
Micronized bP4# Prometrium Pill 100 - 300 NA NA 310 - 60 600 
MPA# Provera Pill 2.5 - 10 NA NA 710 - 1 010 
Estrogen-Progestin Combinations 
Estrogen Progestin 
CEE + MPA Prempro Pill 0.3 - 0.625 1.5 - 5.0 NA 79-175 1 200 - 4 800 
EE + NET-A FemHRT Pill 0.0025 - 0.01 0.5 - 1.0 34 - 38 (EE) ND 4 000 - 10 700 
E2 + NET-A 
Activella, 
Mimvey 
Pill 0.5 - 1.0 0.1 - 0.5 26 - 28 196 - 200 2 375 - 5 250 
Combipatch Patch 0.05 0.14 - 0.25 27 - 71 49 - 78 386 - 1 060 
E2 + DRSP Angeliq Pill 0.5 - 1.0 0.25 - 0.5 30 - 64 166 - 362 2 000- 85 000 
E2 + NGM Prefest Pill 1.0 0.09 39 - 50 285 - 325 515 - 643 
E2 + LNG Climara Pro Patch 0.045 0.015 27 - 54 33 - 82 110 - 194 
Estrogen-SERM Combinations 
CEE + 
bazedoxifene 
Duavee Pill  0.45 + 20 NA ≤ 2 600 ≤ 6 900 (SERM) 
# - progestogen-only products that are generally prescribed in combination with an estrogen only product
NA - not applicable as these HT products do not contain the relevant hormone  
ND - serum concentrations have not been reported  
ae-ao - package inserts can be found at the end of the reference list 
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2.2. Custom-compounded bioidentical hormone therapy 
Custom-compounded bHT refers to the constitution of personalized bHT regimens containing 
class B steroids by compounding pharmacies, and can include any number of bioidentical 
hormones including bioidentical estrone (bE1), estriol (bE3), testosterone (bT), 
dehydroepiandrosterone (bDHEA), bE2 and/or bP4 [77,80]. Unlike FDA-approved HT which 
is available in standardized doses, a customized dose of bHT is prescribed based on a saliva 
test that estimates serum hormone levels [19,95]. However, this method contradicts a global 
consensus that the lowest possible dose of HT that effectively relieves menopausal symptoms 
should be prescribed [20,89,107]. Moreover, numerous studies have shown a poor correlation 
between hormone levels found in saliva and serum, due to saliva hormone levels fluctuating 
based on time of day, diet and other variables [19,20,58,80,95,108].  
The safety and efficacy of custom-compounded bHT is controversial and proponents of 
bioidentical hormones claim that these hormones are natural and identical in structure to 
endogenous human hormones, hence they are safer than conventional HT products [80]. This 
is despite the fact that the proposed ‘natural’ hormones used in custom-compounded bHT are 
in fact semi-synthetic and synthesized in a similar manner to the bioidentical hormones used 
in FDA-approved HT [20,58,80,108]. However, because of this ‘natural’ classification, 
custom-compounding pharmacies may legally dispense products containing bioidentical 
hormones without obtaining FDA-approval for each product [80,108]. This means that 
personalized hormone preparations are dispensed without the rigorous quality control checks 
that FDA-approved drugs are subjected to. Furthermore, unlike conventional HT products, 
custom-compounded bHT products lack black-box warnings of the potential adverse effects of 
HT [17,77,108]. A major concern raised by randomized FDA-checks is the fact that custom-
compounded preparations frequently result in accidental under- or overdosing, possibly due to 
variations in purity and/or human error associated with personalized combination constitution 
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[17,58,77,92,108,109]. Moreover, compounded bHT patches have been shown to yield lower 
serum estrogen levels than bioequivalent standard-dose E2 patches, emphasizing that the 
pharmacodynamics of compounded bHT requires further research and/or regulation [92].  
Clinical trials investigating the safety and efficacy of bP4 creams over a 12-week period have 
revealed that custom-compounded micronized bP4 creams do not relieve vasomotor symptoms, 
nor inhibit the proliferative effects of E2 on the endometrium, nor improve mood swings and 
libido [72,75,110–113]. It has been suggested that this may be due to insufficient bP4 absorption 
and thus low bioavailability [69,70,113–116]. However, the Postmenopausal Estrogen and 
Progestin Intervention (PEPI) trial revealed that oral micronized bP4 effectively relieves 
vasomotor symptoms [117–119], suggesting that oral micronized bP4 may be more effective at 
relieving vasomotor symptoms than localized micronized bP4 creams. 
Custom-compounded bHT often contains bE2 in combination with bE3 and/or bE1 
[17,20,79,80]. Biest or triest combination regimens can be obtained from compounding 
pharmacies, where a biest is composed of bE2 and bE3 in a 20:80 ratio and a triest is composed 
of bE2, bE3 and bE1 in a 10:80:10 ratio [13,19,108,120]. Proponents of bHT claim that bE3 and 
bE1 are weaker, safer estrogens than bE2 [80,120,121] and that bE3 antagonizes the potent 
estrogenic activity of bE2 [19,122]. To the best of our knowledge, however, a detailed 
comparison of the agonist and antagonist properties of these bioidentical hormones for 
transactivation and transrepression via the ER subtypes has not been previously reported. In 
fact, the incorporation of E3 into bHT products appears to be based on murine work conducted 
by Lemon, more than 30 years ago [123,124], showing that E3 was more protective against 
carcinogen-induced neoplasms than E2 or E1 (reviewed in [79]). However, these claims have 
not been validated in human models [122] and large-scale, double-blinded, placebo-controlled 
clinical trials evaluating the safety and efficacy of E3 or bE3 are lacking. However, some 
preliminary small-scale trials have suggested that E3 sometimes relieves vasomotor symptoms 
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but does not protect against bone loss [125,126], while others have provided evidence that E3 
can protect against bone loss [127–131], highlighting the uncertainties regarding E3 use. 
Interestingly, although there are no FDA-approved E3-containing HT products [19], bE3 is used 
in regulated HT products in parts of Europe and Asia [58,132], where it is usually referred to 
as E3 rather than bE3 [133,134].  
Androgens such as bT and bDHEA, are also often used in personalized bHT formulations in 
combination with estrogens and/or progestogens to relieve the symptoms of menopause 
[19,109,120,135]. However, observational studies have reported adverse effects of androgen-
containing HT such as endometrial cancer, hair loss, acne, hirsutism, and deepening of the 
voice [2,109]. In fact, cases of endometrial cancer have been reported in users of oral bHT 
products containing combinations of bE2, bP4, bT and bDHEA or bE1, bE2, bE3, bP4, bT and 
bDHEA [109]. Interestingly, various androgens, including the T precursor, methyltestosterone, 
are approved for HT use in Europe [136], while there is no FDA-approved androgen-containing 
female HT [14,17]. Moreover, although there is a lack of clinical trials examining the 
effectiveness and possible side-effects of androgen use in HT, bT and bDHEA are distributed 
by compounding pharmacies in both the USA [19,58,137] and South Africa [138]. In terms of 
breast cancer risk, the inclusion of bT is especially concerning as T can be aromatized to E2 
within breast tissue [53] and endogenous T levels are only marginally decreased after 
menopause (Table 1). This suggests that the incorporation of bT into an estrogen-containing 
bHT may thus result in greater estrogen exposure than intended, which may increase risk of 
breast cancer development.  
Overall, the lack of large-scale clinical trials investigating the safety and efficacy of custom-
compounded bHT such as biest and triest regimens [20,58], together with the absence of black-
box warnings, lack of thorough regulatory bodies and uncertainties regarding salivary testing, 
has resulted in a consensus between several organizations including the North American 
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Menopause Society (NAMS), The International Menopause Society (IMS), The Endocrine 
Society and The European Menopause and Andropause Society (EMAS) recommending 
against the use of custom-compounded bHT [107]. 
 
3. Hormone therapy and breast cancer risk 
Numerous clinical trials and observational studies have associated conventional HT with 
multiple side-effects such as elevated risk of developing breast-, ovarian- and endometrial 
cancers, as well as cardiovascular disease and stroke [1,2,5,6,9,15,83,117,139–152]. 
Considering that breast cancer is the most common cancer in women worldwide and the leading 
cause of cancer-related deaths in women in developed countries [11,12], the association 
between HT and breast cancer risk is alarming. Although several studies reported adverse 
effects associated with HT prior to 2002 [83,117,146,151], it was the highly publicized findings 
of the Women’s Health Initiative (WHI) [6] that caused alarm and confusion about the safety 
of HT. The WHI study was a large-scale randomized, controlled clinical trial that evaluated the 
benefits and risks of CEE alone in hysterectomized postmenopausal women, or CEE in 
combination with MPA in postmenopausal women with a uterus [6]. The results of the trial 
suggested that CEE-MPA combinations, but not CEE alone, were associated with increased 
invasive breast cancer risk [6]. In contrast, the Million Women Study (MWS), a cohort study 
comprising over one million postmenopausal women from across the United Kingdom, found 
that the use of estrogen alone or estrogen-progestin combinations were both associated with 
increased invasive breast cancer risk [5]. Interestingly, this study found increased breast cancer 
risk with all HT preparations investigated, and no difference in risk between specific estrogens 
(CEE and EE) or progestins (MPA, NET and LNG) [5]. 
Many additional studies investigating breast cancer risk associated with HT use have been 
conducted [8,9,21,83,142–145,149–156], often with contradictory results. For example, while 
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the Women's international study of long-duration oestrogen after menopause (WISDOM) 
clinical trial also found increased breast cancer risk associated with CEE-MPA use [8], the 
Heart and Estrogen/Progestin Replacement Study (HERS) I, HERS II [143] and the Estonian 
postmenopausal hormone therapy (EPHT) clinical trial [144] amongst others [83,145,154,155], 
found no increased breast cancer risk associated with CEE or CEE-MPA. It is thus evident that 
results from the above-mentioned studies are often contradictory and have resulted in much 
confusion regarding the safety of these HT regimens. However, it is noteworthy that the studies 
showing no increased breast cancer risk had significantly less participants [83,143–
145,154,155] than the large-scale WHI, MWS and WISDOM studies [5,6,8]. 
Notably, although most clinical and observational studies investigating the association between 
HT and increased breast cancer risk examined the effects of CEE and MPA, a few studies have 
in fact investigated other estrogens and progestogens. For example, three clinical trials have 
reported no increased breast cancer risk associated with the use of oral E2 alone or in 
combination with NET-A [149,151,152], the latter of which was previously shown to increase 
breast cancer risk when used in combination with CEE in the MWS [5]. Similarly, at least one 
other study reported no increased risk with the use of an E2 only patch [150], while the Estrogen 
in the Prevention of Re-infarction Trial (ESPRIT) found no increased risk with the use of E2 
valerate alone [156]. However, the Kronos Early Estrogen Prevention Study (KEEPS) found 
increased breast cancer risk associated with the use of E2 patches in combination with oral 
micronized P4, while the Early Versus Late Intervention Trial (ELITE) also found increased 
risk with oral E2 used in combination with a P4 vaginal gel (reviewed in [9]). In contrast to the 
above-mentioned studies showing increased breast cancer risk with the inclusion of P4, the 
PEPI trial reported no increased breast cancer risk in women administered CEE plus oral 
micronized P4 or CEE plus MPA [117]. Similarly, the French E3N cohort study found that 
estrogen (CEE or bE2) alone or in combination with oral P4 or dydrogesterone (a P4 isomer not 
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used clinically in the USA) was not associated with increased breast cancer risk. Interestingly, 
results from the same study showed that other estrogen-progestin combinations containing the 
progestins MPA, NET-A, medrogestone, chlormadinone acetate (CMA), cyproterone acetate 
(CPA), promegestone (R5020) or NoMAC, were associated with increased breast cancer risk 
[21,142]. This French cohort study also suggested that administration of oral versus 
transdermal E2 does not influence the degree of breast cancer risk [21,142]. Interestingly, a 
recent Cochrane review examining the adverse side-effects of HT compiled the results of 22 
clinical studies, including most of the above-mentioned studies, and suggested that estrogen-
progestin HT combinations increased breast cancer risk, while use of estrogen-only HT did not 
[9]. It is clear from the above that more clinical studies investigating the association between 
different hormones used in HT and breast cancer are needed. 
Taken together, the evidence in the literature investigating an association between specific 
hormones used in HT and increased breast cancer risk is contradictory. However, there are 
many other hormones used in FDA-approved HT products such as esterified estrogens, E2 
acetate, trimegestone and DRSP, or custom-compounded bHT products such as bE3, bE1 and 
bT, that have not been investigated in large-scale clinical trials or cohort studies, and thus it is 
not known whether these steroid hormones are linked to increased breast cancer risk. At the 
molecular level, steroid hormones predominantly elicit their effects by binding to steroid 
receptors which are ligand-activated transcription factors belonging to the nuclear receptor 
superfamily [157,158].  
 
4. Steroid receptors as mediators of hormone activity and carcinogenesis 
When steroid hormones enter the bloodstream, they bind to various serum binding proteins 
such as sex-hormone-binding globulin (SHBG), corticosteroid-binding globulin (CBG) and/or 
albumin (Table 4). SHBG predominantly binds estrogen and T, while CBG binds cortisol and 
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P4 [159]. The hormones bound to SHBG or CBG are considered unavailable to tissues, while 
the free, unbound hormones and those bound to albumin are considered biologically available 
to enter cells of target tissues and elicit a response by binding to a steroid receptor [160–162]. 
As indicated in Table 4, some estrogens and progestogens bind to SHBG and/or CBG, while 
others do not, resulting in large differences in the availability of estrogens and progestogens 
used in HT. For example, while approximately 37% of serum E2 can bind to SHBG, 16% of E1 
binds, only 1% of E3 binds and EE does not bind at all. As a result, E3, E1 and EE are mostly 
available to enter cells of target tissues (Table 4) suggesting that these estrogens may be more 
abundant than E2 in target tissues, and therefore may compete with E2 for binding to the ER. 
In the same context, progestins also differentially bind to SHBG as shown by 35.5% of NET 
and between 47.5 - 73.6% of LNG binding, while MPA and DRSP do not bind at all (Table 4). 
Considering that the data in Table 4 indicates that progestogens are mostly available, it is 
plausible that even when administered at low concentrations, they may be more abundant in 
target tissues than endogenous steroid hormones, and thus may compete with these hormones 
for binding to their cognate steroid receptors.  
 
Table 4. Binding of hormones to transport proteins [26,31,63,162–166]. 
 
 SHBG (%) CBG (%) Albumin (%) Free (%) Available (%) 
Estrogens 
E2 37 0 61 2 63 
E3 1 0 91 8 99 
E1 16 0 80 4 84 
EE 0 0 99 1  100 
Progestogens 
P4 0.6 17.7 - 36 79.3 - 90.3 0 - 2.4 81.7 - 92.7 
MPA 0 0 88 12 100 
NET 35.5 0 60.8 3.7 64.5 
LNG 47.5 - 73.6 0 25.5 - 50 0 - 2.5 26.4 - 52.5 
DRSP 0 0 95 - 97 3 - 5 100 
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Steroid hormones can permeate the cell membrane and elicit effects by binding to steroid 
receptors, such as the GR and MR, as well as the sex-steroid hormone receptors, the ER, PR 
and AR [157]. A high degree of homology exists between the steroid receptor family, and the 
receptors are organized into four evolutionary-conserved domains (Fig. 2), namely the N-
terminal domain containing the ligand-independent activation function 1 (AF-1) region, the 
highly conserved DNA-binding domain (DBD), a hinge region and a relatively conserved 
ligand-binding domain (LBD) containing an additional ligand-dependent activation function 
(AF-2) region [157,158,167–170]. Generally, unliganded AR, GR and MR are found in the 
cytoplasm, the ER and PR-A predominantly in the nucleus [159,171], while PR-B is distributed 
between the cytoplasm and the nucleus [157,171]. Unliganded steroid receptors are associated 
with chaperone proteins such as heat shock protein (Hsp)90 and Hsp70 [172], but dissociate 
from the chaperone proteins upon ligand binding, as the steroid receptors undergo a 
conformational change [157]. The ligand-bound cytoplasmic steroid receptor can then enter 
the nucleus [157], where it generally binds as a dimer to semi-palindromic DNA sequences 
known as hormone response elements (HREs) to activate target gene expression 
(transactivation) [158,167], or as a monomer to negative-HREs (nHREs) or other DNA-bound 
transcription factors such as nuclear factor kappa B (NFκB), to repress target gene expression 
(transrepression) (reviewed in [167]). Steroid hormones can also elicit non-genomic effects 
either by binding to membrane-bound receptors to activate signaling cascades which ultimately 
result in the downstream regulation of gene expression, or by interacting with membrane 
kinases to activate rapid signaling pathways [167,173–179]. 
The ER, PR, AR and GR are expressed in most breast cancers, and it is therefore not surprising 
that they all play functional roles in breast cancer cell biology (reviewed in [180]). Moreover, 
emerging evidence suggests that their signaling pathways are not always distinct, but are in 
fact extensively intertwined. This too is not surprising considering the high degree of homology  
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Figure 2. A simplified representation of the structure of steroid hormone receptors. These 
receptors contain a variable N-terminal domain (A/B) containing the ligand-independent activation 
function 1 (AF-1) region, a highly-conserved DNA-binding domain (DBD), a hinge region (H) enabling 
flexibility, and a relatively conserved ligand-binding domain (LBD) containing the ligand-dependent 
activation function (AF-2) region. ERα contains an additional C-terminal domain (C) of which the 
function is not known. The values indicated on the right represent the number of amino acids 
constituting each steroid receptor. Figure adapted from [157]. 
 
between the steroid hormone receptors and their cognate DNA-binding sites [157,158,167–
170,181]. In the following sections, the role of steroid receptors and their interplay in breast 
cancer is summarized, with a focus on the known effects of estrogens and progestogens via the 
ER and PR, respectively. 
 
4.1.  Estrogens and the ER 
The first association between estrogen signaling and breast cancer can be traced back to 1896 
[182] and since then, copious in vivo and in vitro studies have shown that estrogens promote 
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breast cancer development and progression [183–195]. Although the precise mechanisms 
whereby estrogens promote breast cancer is still an area of ongoing research, it is well-
established that ERα is crucial for E2-induced breast cancer cell growth [196,197]. This critical 
role for ERα was highlighted by a study showing that E2 exposure did not cause breast cancer 
tumor formation in ERα knockout mice (reviewed in [196,197]). Considering that the ER is 
expressed in approximately 75% of breast cancers, current therapies target ER activity or the 
synthesis of endogenous estrogen [38,49,198]. For example, tamoxifen or fulvestrant are used 
to antagonize ER signaling by blocking or degrading the ER respectively [38,49,198–200], 
while aromatase inhibitors (AIs) are used to decrease the production of endogenous estrogens 
by inhibiting the metabolism of T and androstenedione to E2 and E1 respectively.  
Estrogens and ER signaling lead to the development and progression of breast cancer largely 
through the regulation of gene expression [184,192,201–205]. For example, E2 treatment of the 
MCF-7 breast cancer cell line results in the upregulation of genes encoding growth factors such 
as insulin-like growth factor (IGF)-binding proteins and vascular endothelial growth factor 
(VEGF) [184,201,206–209]. Furthermore, genes regulating the cell cycle such as cyclin D1, 
cyclin A2 and cyclin-dependent kinase 1 (cdk1) are also upregulated by E2 in MCF-7 cells, as 
are genes promoting proliferation such as Ki67 [184,210,211]. In contrast, E2 has previously 
been shown to downregulate the expression of genes inhibiting proliferation such as 
transforming growth factor beta 3 (TGFβ3) [184,210], and genes promoting apoptosis such as 
caspase 9 [184]. ChIP-seq analysis mapped ER-binding sites to the promoter regions of the 
cyclin D1, cyclin A2, cdk1, Ki67 and TGFβ3 genes in response to E2 treatment [210], 
highlighting the role of the ER in mediating the tumor-promoting effects of E2. However, the 
ER subtypes, ERα and ERβ, are known to play different roles in breast cancer [34,212–221]. 
For example, ERα has been shown to promote breast cancer pathogenesis by upregulating the 
expression of cyclin D1, while ERβ inhibited its expression [222]. Interestingly, the role of 
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ERβ is dependent on whether ERα is expressed or not. In the presence of ERα, ERβ can inhibit 
ERα-driven proliferation, while in the absence of ERα, ERβ promotes proliferation [34,212–
221]. The differential action of the ER subtypes may in part be due to the regulation of subtype-
specific target genes [219,220,223–227], possibly due to differences in the N- and C-terminals 
of ERα and ERβ [228]. In addition, ERβ has been shown to downregulate the transcriptional 
activity of ERα by modulating the recruitment of transcription factors required by the ERα 
transcription complex and by increasing ERα degradation [229].  
In addition to the full-length ER subtypes, several ER splice variants have been identified in 
various cell lines, however, it is not clear whether all these variants are also expressed in tissue 
and whether they are functional proteins (reviewed in [230]). An ERα46 splice variant which 
lacks part of the N-terminal domain has in fact been detected in breast tumor tissue, but its 
function is still unknown (reviewed in [228]). In contrast, several ERβ splice variants are 
expressed in breast tissue and have been shown to differentially regulate estrogen signaling 
[231–235]. For example, the ERβcx splice variant contains a unique sequence in its LBD and 
although it cannot bind ligand, it forms heterodimers with ERα, preventing ERα from activating 
gene expression [236]. In contrast, a second ERβ splice variant which also cannot bind ligand, 
forms dimers with either ERα or ERβ, blocking their activity [237].  
From the above, it is clear that the role of E2 and the ER subtypes in breast cancer is complex. 
An added complexity is the fact that many different estrogens are used in HT and it is not clear 
whether these estrogens will elicit similar effects to E2 in the breast context. Studies directly 
comparing the effects of these estrogens on hallmarks of breast cancer such as cell proliferation, 
migration, invasion and apoptosis are scarce. The limited studies that are available suggest that 
while both CEE and E2 increase proliferation, E2 increased proliferation to a greater extent 
[187,238]. Furthermore, at least three studies have directly compared the proliferative effects 
Stellenbosch University  https://scholar.sun.ac.za
 26 
 
of E1, E2 and E3 and although all these studies showed that these estrogens increase breast 
cancer cell proliferation, differences were observed [185,186,189]. For example, Gutendorf 
and co-workers [185] reported potencies in the picomolar range and showed that E2 was more 
potent than E3, while E1 was the least potent. In contrast, Lippman and co-workers [186] 
reported potencies in the nanomolar range and showed that E2 and E1 were equipotent, and 
more potent than E3. From these studies, it is evident that E2 is the most potent estrogen, yet it 
is not clear how the proliferative effects of E1 and E3 compare to E2. Further comparative 
studies are thus required to clarify this ambiguity. Furthermore, although Lippert and co-
workers [189] did not determine potencies, they showed no significant difference in the 
proliferative effects of 10 nM or 100 nM E1, E2 and E3, and showed that while E3 also 
stimulated proliferation at 1 µM and 10 µM, E2 inhibited proliferation and E1 had no effect. 
Interestingly, only Gutendorf and co-workers [185] investigated the proliferative effects of the 
synthetic estrogen, EE, and showed that it was as potent as E2. To the best of our knowledge, 
studies investigating the effects of estrogens on migration, invasion and apoptosis only focused 
on E2 and showed increased migration [239,240] and invasion [239–245], as well as decreased 
apoptosis [245–249], in the ER-positive MCF-7 and T47D breast cancer cell lines.  
In terms of gene expression, two studies have directly compared the EC50 values of E2, E3, E1 
and EE for both ERα- and ERβ-mediated transactivation [29,250], however the EC50 values of 
these studies differed by up to 750-fold for some estrogens. Although both studies found that 
E2 and EE were the most potent estrogens, E3 was the least potent estrogen in one study [250], 
while E1 was the least potent in the other [29]. These discrepancies may be due to the different 
model systems or promoter-reporter constructs used, as the first study used yeast cells and a 
p406-CYC1 yeast expression vector containing two EREs [250], while the latter study used a 
cell line derived from HeLa cells stably expressing a plasmid containing one ERE (HELN cells) 
[29]. In addition to transactivation of gene expression, the estrogen-bound ER can also 
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transrepress gene expression, however there is a paucity of studies characterizing this 
mechanism of action. At least two studies have investigated the efficacy and potency of E2 
and/or EE for transrepression of gene expression via ERα [251,252], however, not much is 
known for other estrogens used in HT or for the transrepressive activities via ERβ. Considering 
the lack of comparative studies and the fact that the effects of bioidentical hormones have not 
been compared to the endogenous human hormones or synthetic estrogens such as EE, it is 
imperative that such molecular studies are conducted. This is critical considering that some 
estrogens used in HT and bHT have not been tested in large-scale, double-blinded clinical trials 
and their safety and efficacy is unknown. 
 
4.2. Progestogens and the PR 
The role of progestogens including natural P4 and progestins in breast cancer is not 
straightforward, as some progestins have been associated with increased breast cancer risk 
[5,6,9,21], while others and P4 have not [21,83,143–145,149,151,152,154,155]. In addition, 
results from studies investigating the effects of progestogens on breast cancer cell proliferation 
are also contradictory. For example, while some studies have shown that P4 [253], R5020 
[254,255], MPA [256,257] and NET-A [256–258] promote proliferation of the MCF-7, ZR75 
or T47D breast cancer cell lines, others have shown that these progestogens are anti-
proliferative in the T47D cell line [259–263]. Some studies have even suggested that P4 and 
the progestin ORG 2058 are proliferative for one cell cycle, after which they exert anti-
proliferative and pro-apoptotic effects [262,263]. Interestingly, the effects of progestogens on 
proliferation also seem to be dependent on the absence or presence of estrogen. For example, 
while progestogens such as P4, MPA, NET, LNG, GES and R5020, have been shown to 
promote proliferation of the MCF-7 cell line, they exerted anti-proliferative effects in the 
presence of E2 [258]. Investigations into the effects of the progestogens on other hallmarks of 
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breast cancer such as apoptosis, migration and invasion are scarce, and results from the limited 
studies are ambiguous. For example, some studies suggest that P4 [256,257], MPA and NET 
increase apoptosis [257], while others suggest that these progestogens inhibit apoptosis 
[256,264]. While it has also been shown that P4, MPA, NES and DRSP can promote migration 
[265–267] and invasion [266–268] in the T47D [266,267] and ZR75 [265,268] breast cancer 
cell lines, MPA was found to promote migration and invasion of the T47D cell line to a greater 
extent than P4, NES and DRSP [267]. Interestingly, P4, NES and DRSP, unlike MPA, reduced 
E2-induced invasion but not migration [267]. In light of the above, it is clear that more 
molecular studies, particularly studies directly comparing the effects of the progestogens on 
hallmarks of breast cancer in the same model system, are needed. 
It is well-known that P4 elicits its biological effects primarily by binding to the PR [269], and 
that progestins were designed to mimic the actions of P4 by also binding to the PR [85,86]. 
However, it is known that some progestins can also bind to and elicit biological effects via 
steroid receptors other than the PR, such as the AR [25] and GR [24]. Thus, whether the 
observed effects of the progestogens on proliferation and other hallmarks of breast cancer are 
mediated by the PR, or any of the other steroid receptors, is still an area of ongoing research. 
However, at least one study has provided evidence that PR knockdown using siRNA [270], 
abrogates MPA-induced breast cancer cell proliferation. 
Three PR isoforms, PR-A, PR-B and PR-C, transcribed from different promoters of a single 
gene, have been identified [43,179]. However, only PR-A and PR-B are functional as PR-C 
lacks a DBD, and thus cannot bind to DNA to activate gene transcription [179,271]. 
Interestingly, approximately 65% of P4-regulated genes are regulated only by PR-B, while 
approximately 4% are regulated only by PR-A and 25% are regulated by both PR isoforms 
[45,49]. These somewhat unique gene sets result in different biological roles for PR-A and PR-
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B, where PR-B mediates P4-induced normal breast cell proliferation [50,51], while P4-bound 
PR-A is implicated in maintaining ovarian and uterine functions [49–51]. The transcriptional 
activity of the individual isoforms is also cell-specific and is extensively regulated by post-
translational modifications including phosphorylation, sumoylation, acetylation and 
ubiquitination (reviewed in [179]). However, PR-A is generally more transcriptionally active 
than PR-B in the absence of ligand [47], while PR-B is more transcriptionally active in the 
presence of agonist [48,49]. The latter may be due to the additional AF-3 region in the N-
terminal domain of PR-B, which enables the binding of cofactors to PR-B that cannot bind PR-
A [272]. 
The PR is a well-known ER-target gene and is thus expressed in most ER-positive breast 
tumors [43,273,274]. Although traditionally thought of only as an indicator of active ER 
signaling pathways in breast cancer tumors, the role of the PR in breast cancer is quite complex 
and dependent on multiple factors such as the relative ratio of PR-A to PR-B [179]. PR-A and 
PR-B are generally expressed at equimolar ratios in the normal mammary gland [275], resulting 
in the formation of PR-A/B heterodimers that regulate a specific gene set (reviewed in [49]). 
In contrast, PR-A and/or PR-B expression is often increased in atypical breast lesions, 
dysregulating the ratio of the PR isoforms [276]. This dysregulation disrupts normal PR 
signaling due to the predominance of one PR isoform and the subsequent formation of 
homodimers that regulate a unique gene set (reviewed in [49]). Interestingly, PR-A is 
upregulated in most ductal carcinomas in situ and invasive breast cancers [275–277] and is 
thought to be more stable than PR-B [48]. Although the exact mechanism behind this has not 
been fully elucidated [48], it may be due to the fact that PR-B contains six more 
phosphorylation sites in its N-terminal domain than PR-A, and the increased kinase activity in 
pre- or early-malignant breast tissue drives PR-B phosphorylation resulting in both PR-B 
hyperactivity and degradation [278,279]. Moreover, the activity of PR-B, as well as the ER, 
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AR, GR and MR, can also be repressed by PR-A under normal cellular conditions 
[157,171,280–286], suggesting crosstalk between steroid receptors. Interestingly, steroid 
receptor crosstalk mechanisms have been described in the breast cancer context. 
 
4.3. Interplay between ERα and the PR 
Recent evidence in the literature suggests that crosstalk between ERα and the PR plays an 
important role in breast cancer pathogenesis [40–42,52]. For example, it has been suggested 
that the potent PR agonist, R5020, promotes breast cancer progression by activating kinase 
cascades via a mechanism requiring both ERα and the PR [287,288]. Furthermore, Giulianelli 
and co-workers [41] provided evidence of an interaction between ERα and the PR in breast 
cancer tissue and cell lines, and showed that this interaction is required for MPA-induced gene 
expression and cell proliferation in the T47D breast cancer cell line. Subsequent studies have 
revealed that the PR can modulate the transcriptional activity and chromatin localization of 
ERα through the formation of these ERα/PR complexes [40–42,52]. For example, Daniel and 
co-workers [52] showed that the unliganded PR can act as a molecular scaffold, resulting in 
PR, ERα, PELP-1 (proline-, glutamic acid- and leucine-rich protein 1) and IGF1 complexes 
that alter ERα gene regulation leading to a more aggressive proliferative response upon E2 
stimulation of the MCF-7 cell line. A second study by Mohammed and co-workers [40] showed 
that P4- or R5020-bound PR is recruited to the ERα complex in both MCF-7 and T47D cells, 
and redirects E2-activated ERα chromatin binding such that the gene expression profile is 
similar to that of PR alone. A similar mechanism was shown by Singhal and co-workers [42] 
in primary ER- and PR-positive human tumors, and is reported to lead to decreased 
proliferation and an improved clinical outcome [40]. The above-mentioned studies suggest that 
an interaction between ERα and the PR can be associated with either poor or good prognosis 
in breast cancer, and that the outcome is determined by the absence or presence of PR ligands. 
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Whether this is true for all PR ligands is not known. This is particularly important for progestins 
used in HT as some progestins from the earlier generations have been implicated in increasing 
breast cancer risk, while clinical trials implicating newer generation progestins that have a 
greater affinity for the PR and elicit biological effects more like P4 than progestins from the 
earlier generations [28,85,86], are mostly lacking. Further studies are thus required to elucidate 
the role of ERα/PR crosstalk in breast cancer pathogenesis in response to different progestins. 
An added complexity in delineating the role of ER/PR crosstalk in response to progestins, is 
the fact that although a few studies report that some progestins and/or their metabolites may 
bind to the ER [29,30,289,290], conflicting results are often reported, and most of these studies 
fail to differentiate between the ER subtypes. Interestingly, it has previously been shown that 
ERα is required at least for MPA-induced breast cancer cell proliferation [41], thus studies 
investigating the estrogenic activity of progestins used in HT and whether ERα is required for 
the effects of all progestins on proliferation are needed. Furthermore, considering that the ERβ 
subtype is also expressed in breast cancers, investigations are required to determine whether a 
similar interaction occurs between ERβ and the PR and what the implications of such an 
interaction would be. Current molecular studies investigating the role of ERβ in breast cancer 
cell biology are however limited, likely due to the lack of an effective commercial antibody for 
this ER subtype [291]. A better understanding of the role of ER/PR crosstalk, and whether it is 
involved in the increased breast cancer risk associated with some progestins, may help with the 
design of a progestin that can be used in HT without breast cancer risk.  
 
4.4. Interplay between the ER and AR 
Many studies have suggested that androgens and the AR play a critical role in breast cancer 
biology (reviewed in [53,54,292–294]) and considering that the AR is expressed in 
approximately 90% of primary breast tumors (reviewed in [53]), it is not surprising that AR-
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targeted treatment for breast cancer is actively being investigated. However, the precise role of 
the AR in breast cancer is dependent on whether ERα is present. While the AR generally plays 
an anti-proliferative role in ER-positive breast tumors by inhibiting the activity of ERα [295–
300], the AR can also mimic the role of ERα in ER-negative breast cancers and promote breast 
cancer development (reviewed in [292]). As a result, clinical trials are currently evaluating the 
use of selective AR modulators in ER-positive breast cancer therapies, and anti-androgens for 
use in ER-negative breast cancer therapies [292]. One suggested mechanism whereby the AR 
can attenuate the activity of ERα is by displacing ERα from ER binding sites, either via binding 
to AREs in close proximity to ER binding sites in estrogen target genes or by competing with 
ERα for binding directly to EREs in target genes [181,301]. Another mechanism may be the 
reported AR-mediated increase in ERβ expression, as it is known that ERβ can inhibit the 
activity of ERα, and that ERβ expression is increased in the presence of natural 
dihydrotestosterone (DHT) or the synthetic androgen mibolerone in MCF-7 and ZR75 breast 
cancer cell lines [302].  
Interestingly, it has been shown that the first-generation progestin MPA is a potent AR agonist 
[25], and that like DHT, it inhibited the transcriptional activity of ERα in MDA-MB-231 breast 
cancer cells overexpressing ERα and the AR [301]. However, AR-mediated effects in breast 
cancer appear to be a double-edged sword. For example, MPA treatment has effectively been 
used to treat breast cancer via a mechanism that potentially promotes AR-induced apoptosis 
[303]. In contrast, MPA used in HT has been associated with increased breast cancer risk 
[5,6,21] by a mechanism possibly involving the disruption of normal AR signaling [37,304]. 
As some progestins can bind to the AR and elicit androgenic effects, while others elicit anti-
androgenic effects, it is important to determine the progestin agonist and antagonist properties 
for AR-mediated transactivation and transrepression of target genes in the same model system. 
We have previously performed these experiments for MPA and NET-A and showed that these 
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progestins display potent AR agonist activity, similar to that of DHT [25]. Considering that 
some progestins that have been reported to increase breast cancer risk can elicit androgenic 
activity, studies are required to determine if ERα/AR crosstalk plays a role in the mechanism 
whereby some progestins increase breast cancer risk.  
4.5. Interplay between the ER and the GR or MR 
Recent studies have also highlighted roles for the GR, MR and their cognate ligands in breast 
cancer cell biology. In terms of the GR and its ligands (glucocorticoids), both are involved in 
mammary gland development during puberty and pregnancy (reviewed in [305,306]). 
Glucocorticoids have also been shown to regulate breast cancer cell proliferation 
[305,307,308], invasiveness, motility and adhesiveness via the GR-mediated upregulation of 
oncogenes and downregulation of metastasis suppressor genes (reviewed in [309]). 
Interestingly, although the GR is expressed in approximately 60% of breast cancers [310], no 
definitive correlation has been found between GR expression and prognosis of breast cancers 
(reviewed in [305]). Some studies, however, suggest that its role may be context-dependent as 
high GR expression has been associated with a good outcome in ER-positive cancers, while it 
is associated with a poor outcome in ER-negative cancers [56]. For example, in ER-negative 
MDA-MB-231 cells, GR activation by dexamethasone (Dex) has been shown to increase the 
expression of genes involved in cell survival, such as serine/threonine protein kinase 1 (SGK1) 
and dual specificity protein phosphatase 1 (DUSP1) [56], while in the mouse xenograft model 
of MDA-MB-231 cells, apoptosis induced by the chemopreventive agent, paclitaxel, was 
inhibited by Dex [56]. In the presence of the ER, however, ERα/GR complexes were formed 
when MCF-7 cells were treated with E2 and Dex, [311,312] resulting in the reprogramming of 
ERα and GR binding sites [312–314], and the subsequent activation of genes associated with 
a more favorable breast cancer outcome [312]. The reprogramming involved an assisted 
loading mechanism which entailed the GR altering the chromatin landscape to expose novel 
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binding sites to which ERα then binds [313,314]. Moreover, Dex has been shown to antagonize 
the proliferative effects of E2 [315], while also inactivating estrogens by sulfation due to the 
activation of estrogen sulfotransferase [305,316]. However, the converse is also true as E2 has 
been shown to decrease GR expression and dephosphorylate the GR, thereby inhibiting 
glucocorticoid action [305,317]. Taken together, although it is clear that the interplay between 
the ER and GR in breast cancer is complex, targeting of the GR in potential novel breast cancer 
therapies should not be excluded.  
The MR has been shown to compensate for the absent GR during specific stages of mammary 
gland development [318], suggesting that the MR may play a similar role to the GR in breast 
cancer cell biology [180]. Although the MR is expressed in most breast cancer tumors [319–
321], little is known about its role in breast cancer pathogenesis. Nevertheless, the MR ligand, 
aldosterone, has been shown to increase breast cancer cell proliferation and migration via a 
mechanism requiring the MR and the G-protein estrogen receptor (GPER), also known as the 
G protein-coupled receptor 30 (GPR30) [322]. This suggests that the MR is also involved in 
crosstalk mechanisms in breast cancer. Interestingly, at least one study has shown that the MR 
and ERα can form a complex in HEK293 cells transiently transfected with cDNA expression 
vectors for the MR and ERα [323], thus it is likely that a similar complex formation may be 
observed in breast cancer cells. Implications of this putative MR and ERα crosstalk is not clear. 
Although beyond the scope of this review, both the GR and MR have also been implicated in 
crosstalk with the PR [324], emphasizing the importance of future studies investigating the 
cellular mechanisms of the GR and MR in breast cancer, as well as the extensive interactions 
between different members of the steroid receptor family. 
5. Conclusion 
Despite the efficacy of FDA-approved conventional HT in relieving the symptoms of 
menopause, its association with increased breast risk is a major concern. Although both 
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estrogen only and estrogen-progestin HT regimens have been associated with increased breast 
cancer risk, findings from various clinical trials indicate that estrogen-progestin combinations 
are associated with a higher risk than estrogen only HT, suggesting that the progestin 
component is responsible for the increased risk. These studies, however, only compared a few 
progestins and considering that many different progestins known to elicit differential effects 
[25,31,325] are available, it cannot be assumed that all progestins would increase breast cancer 
risk. However, the alarm surrounding the associated breast cancer risk has caused some women 
to turn to custom-compounded bHT as an alleged safer, natural alternative. Evidence to support 
the safety and efficacy of these bHT regimens is however lacking and has resulted in many 
associations including the NAMS, IMS, EMAS and Endocrine Society recommending against 
the use of custom-compounded bHT [107]. Considering the large variety of hormones used in 
HT and bHT, and the confusion as to whether any of these regimens are safe in terms of breast 
cancer risk, it is clear that more clinical and molecular studies directly comparing their 
mechanism of action are needed. Molecular studies should include the determination of binding 
affinities, relative agonist and antagonist efficacies and potencies for transactivation and 
transrepression of various estrogens and progestins for individual steroid receptors. Moreover, 
since estrogen-progestin combination regimens are associated with a higher risk than estrogen 
only regimens and that progestins elicit differential effects via steroid receptors, it is possible 
that signaling via multiple steroid receptors may contribute to the observed increased breast 
cancer risk. Furthermore, recent studies have revealed roles for interplay between many of the 
steroid receptors in breast cancer cell biology. If the extensively intertwined nature of steroid 
hormone receptor signaling pathways can be unraveled, it may be possible to elucidate the 
mechanism behind progestin-induced breast cancer and design novel progestins that do not 
increase breast cancer risk. 
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HYPOTHESIS AND AIMS 
 
It is evident from the literature that whether and how estrogens and progestogens used in 
conventional HT increase breast cancer risk remains an enigma. This problem is confounded 
by the fact that many different estrogens and progestins differing in structure and biological 
activity are used in HT. Although proponents of bHT claim that bioidentical hormones used in 
bHT do not increase breast cancer risk, the literature clearly lacks scientific evidence to support 
this claim. In light of this, the primary hypothesis of this thesis was that natural and bioidentical 
estrogens used in HT and bHT, respectively, would elicit similar biological effects to one 
another, but different to a synthetic estrogen via human ERα and ERβ. It was also hypothesized 
that progestins used in HT would elicit differential biological effects to one another and P4 via 
the individual ER subtypes, and on ER-mediated gene regulation and hallmarks of breast 
cancer. Considering that crosstalk between ERα and the PR has been shown to play a critical 
role in breast cancer, we also hypothesized that interplay between these receptors may be an 
underlying mechanism mediating the reputed oncogenic effects of some progestins. 
The aims of this project were three-fold: 
Firstly, the activities of bioidentical E2 (bE2) and E3 (bE3) and synthetic EE were directly 
compared to each other and commercially available E2, E3 and E1 standards. Accurate 
equilibrium dissociation constants (Kd/Ki values) of these estrogens for human ERα and ERβ 
overexpressed in the COS-1 cell line were determined. Relative efficacies and potencies of the 
estrogens for ERα- and ERβ-mediated transcriptional activation and repression were also 
determined in the HEK293 cell line. Using the MCF-7 BUS estrogen-sensitive breast cancer 
cell line that endogenously expresses both ER subtypes, effects on anchorage-independent 
growth were determined as well as the relative efficacies and potencies of the estrogens for 
proliferation and the transactivation and transrepression of two markers of breast cancer, the 
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trefoil factor 1 (pS2) and interleukin-6 (IL-6) genes. Moreover, we investigated the claims that 
E3 and E1 are weak estrogens that possibly antagonize the activity of E2 by evaluating their 
antagonistic effects on gene expression, proliferation and anchorage-independent growth. 
Secondly, the mechanism of action of selected progestins from all four generations, namely 
MPA, NET-A, LNG, GES, NES, NoMAC and DRSP, were characterized relative to each other 
and natural P4, via overexpressed ERα and ERβ in the COS-1 and HEK293 cell lines. We aimed 
to determine precise equilibrium dissociation constants (Kd/Ki values) for the progestins that 
could bind the ER. Furthermore, the relative efficacies and potencies of the estrogenic 
progestins for transcriptional activation and repression were determined in the HEK293 cell 
line. 
Thirdly, using the MCF-7 BUS breast cancer cell line, the effects of MPA, NET and DRSP, 
relative to P4, were assessed on breast cancer cell proliferation, anchorage-independent growth 
and the expression of the ER target genes pS2 and cathepsin D (CTSD), in the absence and 
presence of E2. Relative efficacies and potencies of the selected progestins for breast cancer 
cell proliferation were determined and compared to each other and natural P4. To investigate 
the hypothesis that crosstalk between the PR and ER plays a critical role in mediating the 
oncogenic effects of some progestins, we re-evaluated the effects of the progestogens on gene 
expression, proliferation and anchorage-independent growth in the presence of PR and ER 
antagonists, or siRNA targeting these receptors. Moreover, the recruitment of the PR/ERα 
complex to the promoters of ER and PR target genes implicated in breast cancer progression 
in response to the progestins and P4 was investigated in the absence and presence of E2. 
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Chapter 2 
 
 
A comparative characterization of estrogens used in hormone therapy via 
estrogen receptor (ER)-α and -β 
 
The article in this chapter was published in The Journal of Steroid Biochemistry and Molecular 
Biology, Volume 174, November 2017, pages 27-39, and is presented as it was published in 
combination with the supplementary data to form part of this thesis. Data that is referred to as 
‘data not shown’ in the publication can be found in Appendix B. 
The candidate is the first author and planned and conducted all experimental work, analyzed 
data and wrote the publication. Dr. Renate Louw-du Toit is the co-supervisor of the study and 
contributed to the critical evaluation of the study and editing of the publication. Prof. Donita 
Africander is the supervisor of the PhD study, the corresponding author, and was involved with 
critical evaluation of the study, and editing of the publication.  
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Supplementary Figures 
 
 
 
 
 
 
 
 
 
 
Supplementary Fig. 1. Determination of the equilibrium dissociation constant (Kd) of E2 for ERα and 
ERβ from homologous displacement curves using a global fitting model. The COS-1 cell line transiently 
transfected with a human (A) ERα or (B) ERβ expression vector was incubated with 10 nM or 20 nM 
[3H]-E2 in the absence and presence of increasing concentrations of unlabeled E2 for 4 hours. Counts 
per minute (cpm) were measured and normalized to protein concentration determined using the 
Bradford method [65]. Competition for binding is illustrated by the percentage of [3H]-E2 bound to the 
ER subtypes, where total binding ([3H]-E2 only) in the presence of 20 nM [3H]-E2 was set as 100% and 
all other results set relative to this. Results of at least three independent experiments with each condition 
performed in triplicate (± SEM) are shown.  
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` 
Supplementary Fig. 2. E2 significantly represses TNFα-induced upregulation of gene expression. The 
plots show the fold induction with 0.02 µg/ml TNFα and repression in the presence of 100 nM E2. The 
HEK293 cell line transiently transfected with a human (A) ERα or (B) ERβ expression vector and the 
IL6-NFκB-luciferase promoter-reporter construct or the (C) the MCF-7 BUS cell line, was incubated 
with 0.1% EtOH (vehicle control) or 0.02 µg/ml TNFα in the absence and presence of 100 nM E2. (A, 
B) Luciferase activity was measured in relative light units and normalized to protein concentration 
determined using the Bradford method [65]. (C) Real-time qPCR was performed to determine the 
mRNA expression levels of the IL-6 gene, using GAPDH as the internal standard. Relative gene 
expression of treated samples was calculated relative to the vehicle control (EtOH) which was set as 1, 
with all other responses set relative to this. One-way ANOVA analysis of variance with Newman-Keuls 
post-test was used to determine statistical significance of results.  
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Supplementary Fig. 3. (A) The MCF-7 BUS cell line was incubated with 1 nM E2 (+) in the absence 
and presence of 1 nM E1 (+) and/or 1 nM E3 (+) for 21 days, followed by staining of colonies with 
0.005% crystal violet and (B) quantification using ImageJ software. The pictures in (A) are 
representatives of at least three independent experiments (± SEM). Anchorage-independent growth in 
the presence of 1 nM E2 was set as 100% and all other responses, including the vehicle control, set 
relative to this. One-way ANOVA analysis of variance with Newman-Keuls post-test was used to 
determine statistical significance of results. 
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Retention 
Time (min) 
Observed Accurate 
Mass (M+H)+ 
Derivatized 
Calculated Massa 
Calculated 
Massb 
Derivatized 
Formulaa 
Formulab 
E2 4.68 506.237 506.237 272.388 C30H36NO4S C18H24O2 
bE2 4.70 506.237 506.237c 272.388d C30H36NO4S C18H24O2d 
E3 4.01 522.233 522.231 288.387 C30H36NO5S C18H24O3 
bE3 4.01 522.230 522.231c 288.387d C30H36NO5S C18H24O3d 
a after derivatization with dansyl chloride 
b accepted for E2 and E3 standards prior to derivatization 
c calculated from information given by supplier 
d information given by supplier 
 
 
 
Supplementary Fig. 4. MS spectra of (A) E2 standard, (B) bE2, (C) E3 standard and (D) bE3 after 
derivatization with dansyl chloride, as previously described [2]. Thereafter UPLC-MS was conducted 
using a Waters UPLC Ethylene Bridged Hybrid (BEH) C18 (2.1 mm × 50 mm, 1.7 µm) column 
(ACQUITY UPLC, Waters, Milford, USA). The UPLC mobile phases comprised of 1% formic acid 
(A) and acetonitrile (B). The estrogens were eluted at a flow rate of 0.350 ml/min using a linear gradient 
from 50% A to 100% B in 3.9 minutes, followed by a linear gradient from 100% B to 50% A in 0.1 
minutes. An injection volume of 5 µl was used and accurate mass determinations were conducted using 
a Synapt G2 quadrupole time-of-flight (Q-TOF) mass spectrometer (Waters, Milford, USA) in the 
positive ionisation mode (ESI+). The mass spectrometer was calibrated with sodium formate and 
leucine enkephalkin was used as the reference standard for lock mass. The remaining settings were used 
as previously described [123] and MassLynx V4.1 software (Waters, Milford, USA) was used to 
determine the molecular weights and elemental composition of the estrogens. 
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Supplementary Fig. 5. E2 does not repress TNFα-induced gene expression in the COS-1 cell line. The 
COS-1 cell line was transiently transfected with either a human (A) ERα or (B) ERβ expression vector 
and the synthetic IL6-NFκB-luciferase promoter-reporter construct and incubated with 0.1% EtOH 
(vehicle control) or 0.02 µg/ml TNFα in the absence and presence of 10 µM E2 for 24 hours. Luciferase 
activity was measured in relative light units and normalized to protein concentration determined using 
the Bradford method [65]. 
 
  
A B 
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Supplementary Table 1. Fractional occupancy of the ER subtypes at 100 nM, 1 µM and 10 µM 
ligand.a 
Ligand 
ERα ERβ 
100 nM 1 µM 10 µM 100 nM 1 µM 10 µM 
E2 99.64 99.96 99.99 97.96 99.79 99.98 
bE2 99.91 99.99 99.99 99.06 99.91 99.99 
E3 99.55 99.96 99.99 97.55 99.75 99.97 
bE3 99.69 99.97 99.99 99.15 99.91 99.99 
E1 99.25 99.92 99.99 91.54 99.08 99.96 
EE 99.95 99.99 99.99 99.20 99.92 99.99 
a The fractional occupancy refers to the fraction of receptors that are occupied by the specific ligand at equilibrium and was 
calculated using the equation: Fractional occupancy = [ligand] / ([ligand] + Kd/i). The Kd values of E2 and Ki values of the 
other ligands were obtained from Fig. 1E.  
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Chapter 3 
 
 
Comparing the androgenic and estrogenic properties of progestins used in 
contraception and hormone therapy 
 
The article in this chapter was published in Biochemical and Biophysical Research 
Communications, Volume 491, September 2017, pages 140-146, and is presented as it was 
published in combination with the supplementary data to form part of this thesis. Data that is 
referred to as ‘data not shown’ in the publication can be found in Appendix B. 
The candidate and Dr. Renate Louw-du Toit share first authorship. The candidate planned and 
conducted all experimental work and data analysis pertaining to the estrogen receptor 
experiments, Dr. Renate Louw-du Toit performed the experimental work and data analysis 
pertaining to the androgen receptor. The candidate and Dr. Renate Louw-du Toit co-wrote the 
publication. Professor Janet Hapgood was a study collaborator and was involved with the 
critical evaluation of the study and editing of the publication. Prof. Donita Africander is the 
primary supervisor of the PhD study, the corresponding author, and was involved with the 
critical evaluation of the study, the writing and editing of the publication.
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SUPPLEMENTARY DATA 
Supplementary Table 1. Binding affinities of the ligands for the AR, ERα and ERβ.a 
Ligand 
Kd or Ki (M) ± SEM 
AR ERα ERβ 
MIB 3.19 ± 0.58 x 10-10 - - 
DHT 1.63 ± 1.39 x 10-8 - - 
E2 - 2.35 ± 0.34 x 10
-10 b 2.08 ± 0.68 x 10-9 b 
P4 1.59 ± 0.46 x 10
-8 N.B. N.B. 
MPA 2.21 ± 0.65 x 10-9 N.B. N.B. 
NET-A 3.47 ± 2.22 x 10-9 3.87 ± 1.59 x 10-9 N.B. 
LNG 1.32 ± 0.86 x 10-9 2.40 ± 1.22 x 10-7 N.B. 
GES 4.66 ± 1.90 x 10-11 2.80 ± 1.01 x 10-8 N.B. 
NES 2.41 ± 0.39 x 10-7 N.B. N.B. 
NoMAC 5.76 ± 3.62 x 10-9 N.B. N.B. 
DRSP 1.60 ± 1.39 x 10-8 N.B. N.B. 
aData shown in Fig. 1A and 1E were analyzed using GraphPad Prism software, with non-linear regression 
analysis (one site competition). Kd ± SEM values for MIB and E2 for the AR and ER subtypes, respectively, 
were determined from homologous displacement curves using a global fitting model [4], while Ki ± SEM values 
for the ligands were determined from heterologous displacement curves using the EC50 values, Kd ± SEM values 
for MIB or E2 and the concentration of [3H]-MIB or [3H]-E2, according to the equation by Cheng and Prusoff 
[22].  
bPreviously reported (Perkins et al., unpublished) 
N.B. denotes no binding. 
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Supplementary Table 2. Relative agonist efficacies and potencies of the ligands for 
transactivation via the AR and ERα on a synthetic ARE- or ERE-containing promoter-reporter 
construct, respectively. c 
Ligand 
AR ERα 
MAX (%) ± SEM EC50 (M) ± SEM MAX (%) ± SEM EC50 (M) ± SEM 
MIB 100 ± 0.0 4.42 ± 1.33 x 10-11 - - 
DHT 131.9 ± 7.27 3.39 ± 1.82 x 10-9 - - 
E2 - - 100 ± 0.0 
e 3.09 ± 1.07 x 10-12 e 
P4 18.69 ± 4.16 6.36 ± 3.02 x 10
-6 d N.D. N.D. 
MPA 134.2 ± 23.03 1.32 ± 0.84 x 10-8 N.D. N.D. 
NET-A 67.15 ± 6.13 5.01 ± 1.47 x 10-9 49.0 ± 8.34 2.92 ± 1.27 x 10-8 
LNG 97.65 ± 7.86 2.33 ± 0.15 x 10-9 105.0 ± 16.18 5.70 ± 2.63 x 10-7 
GES 105.5 ± 19.01 1.07 ± 0.03 x 10-9 103 ± 30.28 5.12 ± 1.10 x 10-8 
NES 9.08 ± 7.21 1.33 ± 1.23 x 10-9 d N.D. N.D. 
NoMAC 17.06 ± 1.04 9.28 ± 6.55 x 10-6 d N.D. N.D. 
DRSP 24.13 ± 3.54 7.59 ± 4.95 x 10-7 d N.D. N.D. 
cData shown in Fig. 2A and 2G was analyzed to obtain the relative efficacies (maximal response (MAX) ± 
SEM) and potencies (EC50 ± SEM values) for each ligand for the AR or ERα, respectively.  
dThe EC50 values for NES, NoMAC and DRSP should be interpreted with caution as very weak agonist activity 
was observed. 
ePreviously reported (Perkins et al., unpublished) 
N.D. denotes that no activity could be detected. 
Since the progestogens do not bind to ERβ, no transcriptional activity was determined. 
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Supplementary Table 3. Relative antagonist efficacies and potencies of the ligands for 
transactivation via the AR on a synthetic ARE-containing promoter-reporter construct.f 
Ligand 
AR 
MAX (%) ± SEM EC50 (M) ± SEM 
OHF 100 ± 0.0 2.87 ± 0.62 x 10-8 
P4 85.25 ± 8.39 3.14 ± 1.16 x 10
-8 
MPA N.D. N.D. 
NET-A N.D. N.D. 
LNG N.D. N.D. 
GES N.D. N.D. 
NES 108.1 ± 8.06 5.80 ± 0.89 x 10-7 
NoMAC 93.41 ± 7.12 6.83 ± 0.57 x 10-9 
DRSP 90.01 ± 8.96 1.52 ± 0.23 x 10-8 
fData shown in Fig. 2D was analyzed to obtain the MAX ± SEM and EC50 ± SEM values for each ligand for the 
AR.  
N.D. denotes that no activity could be detected. 
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Supplementary Table 4. Relative agonist efficacies and potencies of the ligands for 
transrepression via the AR and ERα on synthetic NFκB-containing promoter-reporter 
constructs.g 
Ligand 
AR ERα 
MAX (%) ± SEM EC50 (M) ± SEM MAX (%) ± SEM EC50 (M) ± SEM 
MIB 100 ± 0.0 4.24 ± 0.97 x 10-11 - - 
DHT 104 ± 5.98 2.26 ± 2.02 x 10-10 - - 
E2 - - 100 ± 0.0 
i 2.35 ± 0.34 x 10-10 i 
P4 20.92 ± 7.19 1.15 ± 1.03 x 10
-9 h N.D. N.D. 
MPA 90.54 ± 3.63 3.67 ± 2.44 x 10-10 N.D. N.D. 
NET-A 93.51 ± 8.70 1.62 ± 1.06 x 10-10 116.1 ± 2.65 2.18 ± 0.49 x 10-7 
LNG 83.53 ± 11.05 2.77 ± 0.82 x 10-10 55.7 ± 0.68 2.82 ± 0.43 x 10-7 
GES 85.96 ± 4.66 1.88 ± 0.80 x 10-10 101.2 ± 8.69 2.47 ± 1.91 x 10-8 
NES 58.48 ± 4.14 1.48 ± 1.19 x 10-10 N.D. N.D. 
NoMAC 53.12 ± 3.96 4.88 ± 2.70 x 10-10 N.D. N.D. 
DRSP 44.54 ± 1.15 2.48 ± 1.97 x 10-10 N.D. N.D. 
gData shown in Fig. 3A and 3D was analyzed to obtain the MAX ± SEM and EC50 ± SEM values for each 
ligand for the AR or ERα, respectively.  
hAs previously indicated in [12], the EC50 value for P4 should be interpreted with caution as very weak agonist 
activity was observed. 
iPreviously reported (Perkins et al., unpublished) 
N.D. denotes that no activity could be detected. 
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Supplementary Figure 1. (A and B) While only NET-A, LNG and GES bind to human ERα, none of 
the progestogens bind to ERβ. COS-1 cells expressing either human (A) ERα or (B) ERβ were incubated 
for 4 hours with 10 nM [3H]-E2 in the absence or presence of 10 µM E2, P4, MPA, NET-A, LNG, GES, 
NES, NoMAC or DRSP. Counts per minute (cpm) were measured and normalized to protein 
concentration determined using the Bradford method [40]. Specific binding with unlabeled E2 was set 
as 100% and the binding of the unlabeled competitors plotted relative to this.  
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Supplementary Figure 2. NET-A, LNG and GES do not display ER antagonist activity. HEK293 cells 
expressing human ERα and the pGL3-2xERE-pS2-luciferase promoter-reporter plasmid, were treated 
with 1 nM E2 in the absence and presence of increasing concentrations of the well-known ER antagonist 
ICI 182,870 (ICI) (●), NET-A (○), LNG (▼) or GES (▲) for 24 hours. Luciferase activity was 
measured in relative light units and normalized to protein concentration using the Bradford method 
[40]. Results are shown as relative luciferase activity with 1 nM E2 set as 100% and all other responses 
set relative to this.  
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Supplementary Figure 3. (A and B) NES, NoMAC and DRSP, like P4, antagonize MIB-induced 
transrepression. COS-1 cells expressing human AR and the 5xNFκB-luciferase reporter plasmid, were 
treated with 10 ng/ml PMA and 0.1 nM MIB in the absence and in the presence of increasing 
concentrations of P4 (□), MPA (◊), NET-A (○), LNG (▼), GES (▲), NES (■), NoMAC (∆), DRSP (*) 
and the AR antagonist OHF (●) for 24 hours. Luciferase activity was measured in relative light units 
and normalized to protein concentration determined by the Bradford method [40]. Repression with 0.1 
nM MIB was set as 100% and all other responses set relative to this. (C) Maximal response and (D) log 
EC50 values were plotted. (E) NET-A, LNG and GES do not display antagonist activity for 
transrepression via ERα. HEK293 cells expressing human ERα and the p(IL6κB)350hu.IL6P-luciferase 
reporter plasmid, were treated with 20 ng/ml TNFα and 1 nM E2 in the absence and presence of 
increasing concentrations of NET-A (○), LNG (▼), GES (▲) and the ER antagonist, ICI (●) for 24 
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hours. Luciferase activity was measured as above. Repression with 1 nM E2 was set as 100% and all 
other responses set relative to this. 
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Chapter 4 
 
 
Upregulation of estrogen receptor-regulated genes by first generation 
progestins requires both the progesterone receptor and estrogen receptor 
alpha 
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Abstract 
Various progestins, designed to mimic the activity of natural progesterone (P4), are used 
globally in menopausal hormone therapy (HT). Although older progestins such as 
medroxyprogesterone acetate (MPA) and norethisterone (NET) have been implicated in 
increased breast cancer risk, it is controversial whether P4 is associated with increased breast 
cancer risk and little is known regarding newer progestins. Considering that breast cancer is 
the leading cancer-related cause of mortality in women, establishing which progestins increase 
breast cancer risk and elucidating the mechanism behind the increased breast cancer risk is a 
global priority. In this study, we showed for the first time that the newer-generation progestin 
drospirenone (DRSP) is the least potent progestin in terms of proliferation of the estrogen-
responsive MCF-7 BUS cell line, while natural P4 and NET have similar potencies to estradiol 
(E2), which is known to drive breast cancer cell proliferation. Notably, MPA, the progestin 
most frequently associated with increased breast cancer risk, was even more potent than E2. In 
contrast to the differences in potencies for proliferation, we show for the first time that P4, 
MPA, NET and DRSP all induce anchorage-independent growth of the MCF-7 BUS cell line 
to a similar extent as each other and E2. Interestingly, the progestogen-induced proliferation 
and anchorage-independent growth occurs via a mechanism requiring both the progesterone 
receptor (PR) and estrogen receptor (ER). We also show that all the progestogens increased the 
formation of PR/ERα complexes and caused the recruitment of the complex to the promoters 
of the cyclin D1 and MYC PR target genes under both non-estrogenic and estrogenic conditions 
in MCF-7 BUS cells. In contrast, only the older progestins, MPA and NET, caused the 
recruitment of the PR/ERα complex to the promoter region of the trefoil factor 1 (pS2) and/or 
cathepsin D (CTSD) ER target genes, resulting in increased pS2 and CTSD expression under 
both non-estrogenic and estrogenic conditions. These results suggest that progestins 
differentially regulate the manner in which the PR and ER cooperate to modulate the expression 
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of PR and ER regulated genes. Further studies are therefore required to underpin the clinical 
relevance of PR/ERα crosstalk in response to different progestins in both normal and malignant 
breast tissue. Our novel findings highlight differences between natural P4 and progestins and 
emphasizes the importance of comparatively investigating the effects of individual progestins, 
rather than grouping them as a class and assuming that all progestins are the same.  
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1. Introduction 
A variety of progestins are used globally in both contraception and postmenopausal hormone 
therapy (HT) [1–4]. For the latter, progestins are prescribed in combination with an estrogen 
to women with a uterus to prevent the proliferative effects of estrogens on the endometrium 
[2]. Progestins are synthetic progestogens (progesterone receptor (PR) ligands), that are 
classified into four consecutive generations, with the fourth-generation reported to have a 
greater affinity for the PR and elicit effects more similar to natural progesterone (P4) than 
progestins from earlier generations [2,3,5]. For example, we have shown that fourth-generation 
progestins, like P4, display anti-androgenic activity, while the earlier generation progestins 
display androgenic activity [6,7].  
Both progestins and estrogens have previously been implicated in increased breast cancer risk 
[8]. However, HT containing progestins such as first-generation medroxyprogesterone acetate 
(MPA) [8–12] or norethisterone (NET) [8,10,11], have been associated with a higher risk than 
estrogen-only HT (reviewed in [12]). The role of progestins in breast cancer risk is, however, 
not straightforward as some clinical studies have suggested that progestins are not linked to 
increased breast cancer risk [13–21], while some progestins have also been used for breast 
cancer treatment [22–24]. An added complexity is the fact that a diverse range of progestins, 
known to elicit effects different to each other and P4, are available for therapeutic use [6,25–
27]. It is thus evident that large-scale clinical trials and more molecular studies are required to 
directly compare the effects of progestins on breast cancer risk. 
Emerging evidence suggests that the estrogen receptor (ER) is not the only steroid receptor 
implicated in breast cancer pathogenesis, but that other steroid receptors such as the PR, 
previously considered to only be an indicator of a functional ER in breast cancer tumors 
[23,24,28], also plays an important role [29–39]. The role of the PR in breast cancer is however 
complex, as the PR isoforms, PR-A and PR-B, are generally expressed at equimolar ratios in 
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the normal mammary gland, while this ratio is usually dysregulated in breast cancer tissue [40–
42]. Furthermore, the unliganded PR constitutively regulates a gene profile that is distinct from 
the profile regulated by the progestogen-activated PR (reviewed in [43]). Evidence also 
suggests that the formation of ERα and PR complexes can regulate the signaling of these 
receptors [34–36,39,44–50]. For example, a recent study revealed that unliganded PR-B 
enhances ERα-regulated gene expression and breast cancer cell proliferation [36], while 
another study showed that when the PR and ERα are activated, they associate and direct ERα 
to new chromatin binding sites, leading to a gene expression profile that is associated with a 
good prognosis in breast cancer [39]. Moreover, it has been shown that both ERα and the PR 
are required for MPA-induced increased gene expression and breast cancer cell proliferation 
[34].  
Considering that there are many different types of progestins, this study aimed to directly 
compare the effects of selected progestins on breast cancer cell proliferation, anchorage-
independent cell growth and the expression of ER target genes, while also elucidating the role 
of ER and PR signaling in mediating these processes. Since progestins are often co-
administered with estrogens in hormone therapies [51] and breast cancer tumors often have 
high intratumoral estrogen levels [52], we also investigated the effects of estrogen-progestin 
combinations on the above-mentioned responses. Underpinning these mechanisms would 
further our understanding of the differential effects elicited by progestins and whether these 
effects are influenced by the presence of estrogen, all of which may assist in the design of 
hormone therapies with fewer side-effects. 
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2. Materials and Methods 
2.1. Inducing compounds 
Estradiol (E2), P4, MPA, NET, NET-acetate (NET-A), drospirenone (DRSP), mifepristone 
(RU486) and fulvestrant (ICI-182,780; ICI) were obtained from Sigma-Aldrich, RSA. 
 
2.2. Cell culture  
The human MCF-7 BUS breast cancer cell line, received from Prof. Ana Soto (Tufts 
University, Boston), was maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) 
containing 4.5 g/ml glucose (Sigma-Aldrich, RSA), 5% (v/v) heat-inactivated (HI)-fetal calf 
serum (FCS) (Biochrom GmbH, Germany) and 100 IU/ml penicillin and 100 μg/ml 
streptomycin (Sigma-Aldrich, RSA) as previously described [53]. The HEK293 human 
embryonic kidney cell line was obtained from the American Type Culture Collection (ATCC) 
and maintained in DMEM containing 4.5 g/ml glucose, 10% FCS, 100 IU/ml penicillin and 
100 μg/ml streptomycin as previously described [54]. All experiments were conducted in 
charcoal stripped (CS)-FCS and within the first 35 passages since the cell line was thawed from 
storage. Mycoplasma testing was routinely conducted using Hoechst staining [55], and only 
mycoplasma-negative cell lines were used. 
 
2.3. Plasmids 
Human ERα and ERβ encoding cDNA expression vectors (pSG5-hERα and pSG5-hERβ) [56] 
were received from Prof. Frank Gannon (European Molecular Biology Laboratory, Germany), 
while cDNA expression vectors encoding the human PR isoforms (pSG5-hPRA and pSG5-
hPRB) [57] were a gift from Dr. Eric Kalkhoven (University Medical Centre Utrecht, The 
Netherlands). The pGL2basic cDNA expression vector containing no eukaryotic promoter or 
enhancer sequences was obtained from Promega, USA.  
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2.4. Cell viability assays 
MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) cell viability assays were 
conducted as previously described [58] in order to evaluate effects on the proliferation of the 
MCF-7 BUS cell line. Briefly, the cells were treated with 0.1% EtOH (vehicle control), 
increasing concentrations of E2, P4, MPA, NET or DRSP or 100 nM of the progestogens in the 
absence and presence of 1 nM E2, 10 μM ICI or 10 μM RU486. After 48 hours, the cells were 
incubated with pre-warmed MTT solution at a final concentration of 1.25 mg/ml for 4 hours. 
The medium was removed and 200 μl dimethyl sulfoxide (DMSO) added to each well. The 
absorbance at 550 nm was subsequently measured.  
 
2.5. Anchorage-independent growth 
Soft agar assays were conducted as previously described [58]. Briefly, MCF-7 BUS cells were 
incubated with 0.1% EtOH (vehicle control), 100 nM E2, P4, MPA, NET or DRSP or 100 nM 
of the progestogens in the absence and presence of 1 nM E2, 10 μM ICI or 10 μM RU486 for 
21 days. Thereafter, the colonies were fixed with 37% formaldehyde and stained with 0.005% 
crystal violet. Colonies were quantified using ImageJ software (Version 1.49) [59]. 
 
2.6. Small interfering RNA (siRNA) transfections 
MCF-7 BUS cells were seeded into 10 cm2 dishes at a density of 2 x 106 cells in phenol red-
free DMEM supplemented with 5% HI-CS-FCS and 100 IU/ml penicillin and 100 μg/ml 
streptomycin. The next day the cells were transfected with either 10 nM non-silencing 
scrambled sequence control (NSC) siRNA (Qiagen, USA) or siRNA directed against the 
human PR isoforms (GS5241; a combination of 4 target-specific siRNAs, Qiagen, USA), or 
25 nM NSC siRNA or siRNA directed against human ERα (SC-29305; a combination of 4 
target-specific siRNAs, Santa Cruz, Germany), using Dharmafect transfection reagent 
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(Dharmacon, USA) as per the manufacturer’s instructions. After 24 hours, the cells were 
replated into 12-well plates at a density of 2 x 105 cells per well. The next day, cells were 
treated with 0.1% EtOH (vehicle control), or 100 nM MPA or NET in the absence and presence 
of 1 nM E2, or 100 nM E2 only for 24 hours. For the quantification of mRNA expression by 
real-time quantitative PCR (qPCR), total RNA was harvested and cDNA synthesized. 
Reduction in protein levels was confirmed by immunoblotting.  
 
2.7. Isolation of total RNA, cDNA synthesis and real-time qPCR 
MCF-7 BUS cells were plated and treated as described in Section 2.6. Total RNA was isolated 
using Tri-reagent (Sigma-Aldrich, RSA) and reverse transcribed using the ImProm-IITM 
Reverse Transcription System (Promega, USA) as per the manufacturer’s instructions. Real-
time qPCR was performed using the KAPA SYBR® FAST ABI Prism qPCR Kit (Roche 
Applied Science, RSA) according to the manufacturer’s instructions. The mRNA expression 
of pS2 (trefoil factor 1), CTSD (cathepsin D) and the reference gene GAPDH (glyceraldehyde 
3-phosphate dehydrogenase) was measured using the primer sets described in Table 1. Agarose 
gel electrophoresis and melt curve analyses were performed to confirm the presence of the 
amplicon of the correct size (data not shown). The primer efficiency of each primer set was 
determined using a cDNA dilution series to generate standard curves (data not shown). The 
efficiencies were 1.99, 1.93 and 1.86 for pS2, CTSD and GAPDH, respectively. Relative 
transcript levels were determined as previously described [60]. 
 
2.8. Co-immunoprecipitation (Co-IP) assays 
Co-IP assays were conducted as previously described [61], with a few modifications. MCF-7 
BUS cells were seeded into 10 cm2 dishes at a density of 2 x 106 cells in phenol red-free DMEM 
supplemented with 5% HI-CS-FCS and 100 IU/ml penicillin and 100 μg/ml streptomycin. 
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Table 1. Primers used for real-time qPCR.  
Gene  Primer sequence 
Amplicon 
Length 
Ref. 
pS2  
5’-ATACCATCGACGTCCCTCCA-3’ (fwd) 
5’-AAGCGTGTCTGAGGTGTCCG-3’ (rev) 
147 bp [62] 
CTSD  
5’-GCGAGTACATGATCCCCTGT-3’ (fwd) 
5’-CTCTGGGGACAGCTTGTAGC-3’ (rev) 
89 bp [63] 
GAPDH  
5’-TGAACGGGAAGCTCACTGG-3’ (fwd) 
5’-TCCACCACCCTGTTGCTGTA-3’ (rev) 
307 bp [64] 
 
The following day cells were treated with 0.1% EtOH (vehicle control) or 100 nM E2, MPA or 
NET for one hour. Cells were subsequently washed with ice-cold PBS and harvested in 500 µl 
RIPA buffer (10 mM HEPES, 10 mM KCl, 1.5 mM MgCl2 and 0.1% nondidet P-40 substitute 
(Roche Applied Science, RSA)), containing protease inhibitors. An aliquot was removed for 
input controls and the remaining lysate incubated for one hour with protein A/G PLUS agarose 
beads pre-blocked with salmon sperm DNA before an overnight incubation on a rotating wheel 
with antibodies against ERα (sc-8002, Santa Cruz Biotechnology, Germany), PR (PGR-312-
L-CE, Leica Biosystems, UK) or IgG (IgG control, sc-2027, Santa Cruz Biotechnology, 
Germany). The antibody-bound proteins were released from the beads by boiling in 2xSDS-
sample buffer [65] and the supernatants subjected to immunoblotting. 
 
2.9. Immunoblotting 
HEK293 cells were transiently transfected with the pGL2basic empty vector (negative control) 
or cDNA expression vectors for human ERα, PR-A and PR-B (positive controls). After 48 
hours, cells were lysed with 2xSDS-sample buffer [65] and boiled at 97°C for 10 minutes. 
HEK293 cell lysates and MCF-7 BUS cell lysates from siRNA transfections (Section 2.6.) and 
Co-IP assays (Section 2.8.) were subjected to electrophoresis on a 10% SDS-polyacrylamide 
gel, and subsequently transferred to nitrocellulose membranes (AEC Amersham, RSA). The 
membranes were then probed with primary antibodies specific for ERα, PR or the loading 
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control, GAPDH (0411, Santa Cruz Biotechnology, Germany), followed by incubation with a 
horseradish peroxidase (HRP)-conjugated secondary antibody (anti-mouse, sc-2005, Santa 
Cruz Biotechnology, Germany). Proteins were visualized using enhanced chemiluminescence 
(Biorad, RSA) and a MyECL imager (Thermo Scientific, USA) and quantified using ImageJ 
software (version 1.49) [59]. 
 
2.10. Chromatin immunoprecipitation (ChIP) and re-ChIP assays 
ChIP and re-ChIP assays were conducted as previously described [61,66–68], with a few 
modifications. Briefly, MCF-7 BUS cells were seeded into 10 cm2 dishes at a density of 2 x 
106 cells in phenol red-free DMEM supplemented with 5% HI-CS-FCS and 100 IU/ml 
penicillin and 100 μg/ml streptomycin. After 24 hours, the cells were treated with 0.1% EtOH 
(vehicle control) or 1 nM MPA or NET in the absence and presence of 1 nM E2, or 1 nM E2 
only for 2 hours. Cells were harvested in PBS containing protease inhibitors once the chromatin 
and proteins were cross-linked with 1% formaldehyde. The lysate was subsequently sonicated 
and 30 µg used as input controls. Approximately 100 µg of chromatin was immunoprecipitated 
with antibodies specific for ERα, PR or IgG, followed by the collection of chromatin using pre-
blocked protein A/G-PLUS agarose beads. After thorough washing steps, the DNA-protein 
complexes were eluted. For ChIP assays a 1% SDS, 100 mM NaHCO3 elution buffer was used, 
and for re-ChIP assays a 1% SDS, 10 mM dithiothreitol elution buffer containing protease 
inhibitors was used. For re-ChIP assays, an aliquot of the supernatant was used as confirmation 
that the first immunoprecipitation was successful, and the remaining chromatin was re-
immunoprecipitated with anti-ERα, anti-PR or anti-IgG antibodies. The cross-linking of all the 
DNA-protein eluents was then reversed by adding NaCl, followed by incubation overnight at 
65°C. Proteinase K (Roche Applied Science, RSA) was added to the samples the following day 
and incubated at 45°C for 1 hour for protein digestion. The input and immunoprecipitated 
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samples were subsequently purified using the Machery Nagel NucleoSpin® Extract II kit 
(Separations, RSA) as per the manufacturer’s instructions. Purified DNA samples were 
analysed by real-time qPCR using the primer sets described in Table 2.  
Table 2. ChIP and re-ChIP primers used for real-time qPCR.  
Gene Primer Sequence 
Amplicon 
Length 
Ref. 
pS2 
5’-ATTAGCTTAGGCCTAGAC-3’ (fwd) 
5’-CTGAGGGATCTGAGATTCA-3’ (rev) 
257 bp [62] 
CTSD 
5’-TCCAGACATCCTCTCTGGAA-3’ (fwd) 
5’-GGAGCGGAGGGTCCATTC-3’ (rev) 
240 bp [69,70] 
CCND1 
5’-CCTGCTGGGGCAACCCATCG-3’ (fwd) 
99 bp [34] 
5’-CCCTCCCCCGCCGGGAATTA-3’ (rev) 
MYC 
5’-TCTCTGCTGACTCCCCCGGC-3’ (fwd) 
71 bp [34] 
5’-CCGCGGGACCGGACTTCCTA-3’ (rev) 
 
2.11. Data manipulation and statistical analysis  
Data manipulation, graphical presentations and statistical analysis were performed using 
GraphPad Prism® version 5 (GraphPad Software). Non-linear regression analysis was used to 
determine efficacies and potencies. One-way ANOVA analysis of variance with Newman-
Keuls (compares all pairs of columns) post-test was used to determine statistical significance 
of results. Statistically significant differences are indicated by the letters ‘a’, ‘b’, ‘c’, etc., where 
significantly different values are assigned a different letter, or * (p < 0.05), ** (p < 0.01) or 
*** (p < 0.001). Non-significant differences are indicated by ns (p>0.05).  
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3. Results 
3.1. P4, MPA, NET and DRSP increase proliferation and anchorage-independent growth of 
the estrogen-responsive MCF-7 BUS breast cancer cell line  
Progestins often elicit biological effects that are distinct from each other and natural P4 
(reviewed in [2,26]). Indeed, studies have shown that some progestins are linked to increased 
breast cancer risk (reviewed in [12]), while most studies suggest P4 is not [10,11,71]. We 
therefore directly compared the effects of the older first-generation progestins MPA and NET-
A, as well as the newer fourth-generation progestin DRSP, relative to each other and natural 
P4 on cell proliferation and anchorage-independent growth. In addition, we investigated 
whether the progestogens could antagonize the effects of E2. MPA and NET-A were included 
in this study as they have both been linked to increased breast cancer risk [8], but are known to 
differentially activate steroid receptors such as the glucocorticoid receptor (GR) [25] and ERα 
[6]. DRSP was included as it is a progestin reported to elicit effects similar to P4, but dissimilar 
to MPA and NET-A [6,72,73]. As NET-A administered in HT is rapidly metabolized to active 
NET [74], we included both NET-A and NET in this phase of the study to exclude the 
possibility that the acetate elicits different effects in the MCF-7 BUS cell line. This cell line 
was thus incubated with increasing concentrations of E2, P4, MPA, NET-A, NET and DRSP, 
or 1 nM E2 in the absence and presence of 100 nM progestogens for 48 hours after which 
proliferation was quantified using the MTT cell viability assay. Since the MCF-7 BUS cell line 
is estrogen-sensitive [75] and highly proliferative in response to E2 treatment, we included 
treatment with E2 alone as a positive control. For anchorage-independent growth of the MCF-
7 BUS cell line, the soft agar assay was used to quantify the number of colonies formed in the 
presence of 100 nM progestogens in the absence and presence of 1 nM E2 for 21 days. 
Surprisingly, the selected progestins and P4 had similar efficacies for proliferation of the 
estrogen-responsive MCF-7 BUS cell line to each other and E2 (Fig. 1A and 1B). However, 
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while P4, NET-A and NET were equipotent to E2 and each other, MPA was approximately 20-
fold more potent than E2, and DRSP approximately 1600-fold less potent (Fig. 1C). The 
maximal responses (efficacies) and EC50 values (potencies) for proliferation are summarized 
in Fig. 1D. In terms of anchorage-independent growth, no differences were observed in the 
number of colonies obtained with any of the test compounds (Fig. 1F) and unlike the potent 
ER antagonist ICI, the progestogens did not modulate E2-induced cell proliferation (Fig. 1G) 
or anchorage-independent growth (Fig. 1H). In agreement with the study by Govender et al. 
showing that NET-A and NET elicit similar effects to each other on gene expression in the 
HeLa and End1/E6E7 cell lines [25], we show that NET-A and NET induce similar increases 
in proliferation (Fig. 1A and 1D) and anchorage-independent growth (Fig. 1E and 1F). Further 
experiments were thus only performed with the active metabolite NET. 
 
3.2. Progestogen-induced breast cancer cell proliferation and anchorage-independent 
growth is abrogated by ICI and RU486 
Since the PR ligands displayed similar effects to E2 on breast cancer cell proliferation and 
anchorage-independent growth in the estrogen-responsive MCF-7 BUS cell line, we next 
investigated the contributions of both the PR and ER towards mediating these effects. MCF-7 
BUS cells were incubated with 100 nM P4, MPA, NET or DRSP in the absence and presence 
of the ER antagonist, ICI, or the PR antagonist, RU486. Results show that both ICI and RU486 
abrogated progestogen-induced proliferation (Fig. 2A) and anchorage-independent growth 
(Fig. 2B and 2C). Responses obtained in the presence of RU486 should, however, be 
interpreted with caution as it antagonizes not only the PR, but also the androgen receptor (AR) 
and GR [7,76,77]. Nevertheless, it is likely that the progestogen effects on proliferation and 
anchorage-independent growth are indeed mediated by the PR since we know that all these  
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Figure 1 legend on next page. 
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Figure 1. The progestogens display similar efficacies, but not potencies, for increased breast 
cancer cell proliferation and promote anchorage-independent growth of MCF-7 BUS cells to the 
same extent. The MCF-7 BUS cell line was incubated with EtOH (vehicle control) or (A) increasing 
concentrations of E2 (■), P4 (●), MPA (▲), NET-A (▼), NET (♦) or DRSP (×) or (G) 1 nM E2 in the 
absence and presence of 100 nM progestogens or 10 µM ICI, for 48 hours. Cell proliferation was 
quantified using the MTT cell viability assay. (B) Plots of the maximal response and (C) log EC50 values 
of the test compounds for proliferation from Fig. 1A are shown and these values are reported in (D). 
(E, F and H) MCF-7 BUS cells were incubated with EtOH (vehicle control) or 100 nM progestogens 
in the absence and presence of 1 nM E2 for 21 days. After 21 days, colonies were stained with 0.005% 
crystal violet and (F and H) quantified using ImageJ software (Version 1.49). Results shown are 
representatives of at least three independent experiments, with the response obtained in the presence of 
the vehicle control set as one, and all other responses set relative to this. One-way ANOVA analysis of 
variance with Newman-Keuls post-test was performed to determine statistical differences. 
 
progestogens are PR agonists, while NET and DRSP are not GR [73,78] agonists and P4 and 
DRSP are AR antagonists [6]. 
 
3.3. P4, MPA, NET and DRSP differentially regulate the mRNA expression of the ER-
regulated pS2 and CTSD genes in an ER- and PR-dependent manner 
Considering that we showed that progestogen-induced breast cancer cell proliferation and 
anchorage-independent growth requires the ER, we next investigated whether the selected 
progestogens could modulate the mRNA expression of the ER-regulated pS2 and CTSD genes 
and whether these effects would be altered in the presence of E2. The pS2 gene is a well-known 
marker of breast cancer that is upregulated in ER positive tumors and associated with disease 
progression [79], while CTSD is linked to breast cancer metastasis, invasion, relapse and short 
disease survival [80]. MCF-7 BUS cells were thus incubated for 24 hours with 100 nM P4, 
MPA, NET and DRSP in the absence and presence of 1 nM E2, or with 100 nM E2 only. Results 
showed that MPA was the only progestogen to increase pS2 mRNA expression and to a similar 
extent as E2 (Fig. 3A), while both MPA and NET significantly increased CTSD mRNA   
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Figure 2. Progestogen-induced breast cancer cell proliferation and anchorage-independent 
growth is inhibited by both ICI and RU486. The MCF-7 BUS cell line was incubated with either 
EtOH (vehicle control) or 100 nM P4, MPA, NET or DRSP in the absence and presence of 10 μM ICI 
or 10 µM RU486 for (A) 48 hours or (B) 21 days. (A) Cell proliferation was quantified using the MTT 
cell viability assay, while (B) anchorage-independent growth was quantified using the soft agar assay. 
(C) The colonies formed (in Fig. 2B) were quantified using ImageJ software (Version 1.49). Results 
are shown as (A) relative proliferation or (C) relative colony formation with the response obtained with 
the vehicle control set as one, and all other responses set relative to this. Results shown in (A) and (C) 
are the averages of at least three independent experiments, while (B) is a representative figure. 
 
expression, albeit to a lesser extent than E2 (Fig. 3B). Interestingly, treatment with progestogen 
in the presence of E2 compared to E2 alone, resulted in similar increases in pS2 (Fig. 3C) and 
CTSD (Fig. 3D) mRNA expression. Knowing that both MPA and NET can bind to the PR, 
whilst NET-A, but not MPA, can bind to ERα [6], and that both the PR and ER are required 
for progestogen-induced breast cancer cell proliferation and anchorage-independent growth, 
we next investigated the role of the PR isoforms and ERα in mediating the effects of MPA 
and/or NET on these genes. MCF-7 BUS cells transfected with non-silencing control (NSC),   
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Figure 3. The progestogens differentially modulate pS2 and CTSD mRNA expression and do not 
alter E2-induced pS2 and CTSD mRNA expression. MCF-7 BUS cells were treated with EtOH 
(vehicle control) or (A and B) 100 nM E2, P4, MPA, NET or DRSP, or (C and D) 100 nM progestogen 
in the absence and presence of 1 nM E2 for 24 hours. Total RNA was isolated, reverse transcribed and 
real-time qPCR conducted to determine the relative expression of (A and C) pS2 and (B and D) CTSD 
mRNA levels relative to that of GAPDH (reference gene). The vehicle control was set as one and the 
relative mRNA expression of pS2 and CTSD in the treated samples set relative to this. Results shown 
are the averages of at least three independent experiments.  
 
PR-A/B or ERα siRNA were incubated with 100 nM E2, MPA or NET for 24 hours. Western 
blotting (Fig. 4A and 4B) confirmed that transfection of the MCF-7 BUS cell line with PR-A/B 
siRNA resulted in a 73% and 71% knockdown of PR-A and PR-B respectively, while ERα 
siRNA resulted in a 60% decrease in ERα expression, as well as 80% knockdown of PR-A and 
86% knockdown of PR-B. The fact that knockdown of the ER causes a reduction in PR levels 
was not completely unexpected as it is well-known that the PR is an ER target gene [81], and 
this reduction has in fact been shown previously [82]. Both PR and ERα knockdown abrogated   
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Figure 4. Both the PR and ERα are required the upregulation of ER-regulated genes by MPA 
and/or NET. MCF-7 BUS cells transfected with (C, D) 10 nM NSC or PR-A/B siRNA or (E, F) 25 
nM NSC or ERα siRNA were treated with EtOH (vehicle control) or 100 nM E2, MPA or NET for 24 
hours. (A) For verification of PR-A/B or ERα knockdown, total protein from the MCF-7 BUS cells 
transfected as described above was harvested, and western blotting performed using antibodies specific 
for ERα, PR-A/B and GAPDH. A representative blot is shown and (B) PR-A, PR-B and ERα expression 
levels were quantified relative to the GAPDH loading control using ImageJ software (Version 1.49). 
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Western blots of three independent experiments were quantified to determine the percentage protein 
knocked down. (G and H) MCF-7 BUS cells were treated with EtOH (vehicle control) or 100 nM E2, 
MPA or NET in the absence and presence of 10 µM ICI for 24 hours. (C-H) Total RNA was isolated, 
reverse transcribed and real-time qPCR was conducted to determine the relative expression of (C, E, 
G) pS2 and (D, F, H) CTSD mRNA levels relative to GAPDH. The vehicle control of each condition 
was set as one and the relative mRNA expression in the treated samples set relative to this. Results 
shown are the averages of at least three independent experiments. 
 
MPA-induced pS2 (Fig. 4C and 4E) and CSTD (Fig. 4D and 4F) mRNA expression, as well as 
the NET-induced CTSD mRNA expression (Fig. 4D and 4F). As expected, ERα knockdown, 
but not PR knockdown, abrogated the E2-induced increase in both pS2 (Fig. 4C and 4E) and 
CTSD (Fig. 4D and 4F) mRNA expression. Considering that ERα knockdown also silenced PR 
expression, we confirmed that the ER is required for the upregulation of pS2 (Fig. 4G) and 
CTSD (Fig. 4H) mRNA expression by MPA and/or NET using ICI to antagonize the ER, as 
ICI does not decrease PR levels [83]. 
 
3.4. MPA and/or NET treatment results in co-recruitment of the PR and ERα to the pS2 and 
CTSD promoters 
Given that we show that both ERα and the PR are required for MPA- and/or NET-induced 
regulation of ER-target genes, we next investigated whether MPA or NET treatment results in 
the formation of PR/ERα complexes in the MCF-7 BUS cell line. The cells were incubated 
with 100 nM MPA, NET or E2 for 1 hour followed by immunoprecipitation using a PR-A/B- 
or an ERα-specific antibody, and western blot analysis confirmed that PR-A, PR-B and ERα 
are present in all input samples (Fig. 5A). Results from Co-IP assays (Fig. 5B and 5C) 
confirmed previous findings that these steroid receptors occur in a complex both in the absence 
and presence of ligand [34,39] and revealed that both MPA and NET treatment resulted in 
increased PR-A and PR-B complexed with ERα (Fig. 5B - 5E). As expected, the E2 control did   
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Figure 5. PR-A, PR-B and ERα occur in a molecular complex. MCF-7 BUS cells were incubated 
with 100 nM E2, MPA or NET for 1 hour, after which cell extracts were immunoprecipitated (IP) with 
either an (B) ERα- or a (C) PR-A/B-specific antibody. (A-C) Immunoblotting (IB) was performed using 
antibodies specific for ERα, PR-A/B or GAPDH (internal control) and a representative blot is shown. 
(D and E) At least three independent experiments were quantified in terms of ERα, PR-A and PR-B 
expression levels relative to the respective input controls as well as GAPDH expression using ImageJ 
software (Version 1.49). The vehicle control of each condition was set as one and all other responses 
set relative to this.  
 
not modulate the amount of PR-A and PR-B complexed with ERα (Fig. 5B - 5E). Considering 
that the PR isoforms and ERα occur in a complex in MCF-7 BUS cells, and that both receptors 
are required for MPA- and NET-induced pS2 and/or CTSD expression, we next investigated 
whether MPA or NET treatment would cause the PR and ERα to be co-recruited to the 
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promoters of the endogenous pS2 and CTSD genes. In Fig. 6A we show a schematic 
representation of the pS2 and CTSD gene promoters, indicating the primers used in ChIP/re-
ChIP/qPCR analysis and the relevant cis-elements. MCF-7 BUS cells were incubated for 2 
hours with 1 nM MPA or NET in the absence and presence of 1 nM E2, or with 1 nM E2 only, 
after which ChIP and re-ChIP assays were performed. As expected, E2-treatment resulted in 
the recruitment of ERα (Fig. 6B and 6D), but not the PR (Fig. 6C and 6E), to the pS2 and CTSD 
promoters. In contrast, MPA treatment resulted in recruitment of both the PR and ERα to both 
promoters (Fig. 6B - 6E), while NET treatment also resulted in their recruitment to the CTSD 
promoter (Fig. 6D and 6E). We also showed that this recruitment was not modulated under 
estrogenic conditions (Fig. 6B - 6E). To determine whether the PR and ERα are in fact co-
recruited to these promoters, we next performed re-ChIP assays. MCF-7 BUS cells were 
incubated with the test compounds and then subjected to immunoprecipitation with an anti-IgG 
antibody (negative control) or a PR-A/B-specific antibody followed by an ERα-specific 
antibody, and vice versa. Results show that the PR and ERα are co-localized on the endogenous 
pS2 (Fig. 7A) and CTSD (Fig. 7D) promoters in the presence of MPA, and on the CTSD 
promoter in the presence of NET (Fig. 7E). E2 did not modulated the progestin-induced co-
localization (Fig. 7B and 7F) or cause any co-localization on its own (Fig. 7C and 7G). 
 
3.5. ERα and the PR are co-recruited to PR binding sites in the CCND1 and MYC promoters 
So far, this study has provided evidence that MPA and/or NET, but not P4 and DRSP, can 
increase the expression of ER-target genes implicated in breast cancer via a mechanism 
involving the co-localization of the PR and ERα on the promoters of these genes. Interestingly, 
co-localization of these receptors in the presence of MPA has also been shown on known PR 
binding sites in the promoters of the progestogen-responsive proto-oncogenes CCND1 (cyclin 
D1) and MYC in the T47D breast cancer cell line [34]. Considering that MPA has previously   
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Figure 6. ERα and the PR are recruited to the pS2 promoter in response to MPA treatment, and 
to the CTSD promoter in response to MPA or NET treatment. MCF-7 BUS cells were incubated 
with EtOH (vehicle control), 1 nM E2, or 1 nM MPA or NET in the absence and presence of 1 nM E2 
for 2 hours, followed by the ChIP assay. (A) Schematic representation of cis-elements in the promoter 
regions of pS2 (adapted from [84,85]) and CTSD (adapted from [80,86]) and the ChIP/qPCR primer 
positions. Cell lysates were immunoprecipitated (IP) with antibodies specific for IgG (negative control), 
(B and D) ERα, or (C and E) PR-A/B, followed by real-time qPCR analysis of the resulting 
immunoprecipitated DNA fragments and input controls. Data shown was normalized to input and IgG 
controls and expressed as the fold response relative to the vehicle control set as one. Results shown are 
the averages of three independent experiments. 
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Figure 7. MPA causes the co-recruitment of ERα and the PR to the pS2 promoter, while both 
MPA and NET result in co-recruitment to the CTSD promoter. MCF-7 BUS cells were incubated 
with EtOH (vehicle control), 1 nM MPA or NET in the absence and presence of 1 nM E2, or with 1 nM 
E2 only, for 2 hours followed by re-ChIP assays. Cell lysates were subjected to immunoprecipitation 
(IP) with an anti-IgG antibody (negative control) or an ERα-specific antibody followed by a PR-A/B-
specific antibody, and vice versa, prior to real-time qPCR analysis of the resulting immunoprecipitated 
DNA fragments and input control. Data shown was normalized to input and IgG controls and expressed 
as the fold response relative to the vehicle control set as one. Results shown are the averages of three 
independent experiments. 
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been shown to regulate gene expression in a promoter- and cell-specific manner [68,87], we 
next determined whether MPA, as well as P4, NET or DRSP, would induce PR and ERα co-
localization on these gene promoters in MCF-7 BUS cell line. Moreover, we investigated these 
effects under estrogenic and non-estrogenic conditions. MCF-7 BUS cells were incubated with 
1 nM P4, MPA, NET or DRSP in the absence and presence of 1 nM E2, or with 1 nM E2 only, 
for 2 hours after which ChIP and re-ChIP assays were performed. In agreement with the 
findings of Giulianelli and co-workers [34], our results indicated that MPA treatment induced 
PR and ERα co-localization on both the CCND1 and MYC promoters in MCF-7 BUS cells (Fig. 
8C and 8G). Furthermore, this co-localization was not unique to MPA, but was also observed 
in MCF-7 BUS cells treated with P4 (Fig. 8B and 8F), NET (Fig. 8D and 8H) or DRSP (Fig. 
8E and 8I). Moreover, progestin treatment under estrogenic conditions did not modulate the 
response observed under non-estrogenic conditions. 
 
4. Discussion 
In this study, we show that the first-generation progestins MPA and NET, the fourth-generation 
progestin DRSP, and natural P4 increase breast cancer cell proliferation and anchorage-
independent growth of the MCF-7 BUS breast cancer cell line (Fig. 1A-1F). Notably, the 
observed responses were similar both in the absence and presence of E2 (Fig. 1G and 1H). We 
also show that DRSP is the least, and MPA the most potent progestin in terms of proliferation, 
suggesting that HT containing the newer generation progestin DRSP may pose less breast 
cancer risk than HT containing MPA or NET. Although inhibition with ICI abrogated the 
effects of the progestogens on both proliferation and anchorage-independent growth, 
suggesting a mechanism requiring the ER, co-treatment with RU486 also abrogated these 
responses (Fig. 2). Considering that RU486 can antagonize the PR, GR and AR, this result does 
not definitively reveal which of these receptors are required for progestogen-induced breast   
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Figure 8. All the progestogens result in co-localization of the PR and ERα on both the CCND1 
and MYC promoters. MCF-7 BUS cells were incubated with EtOH (vehicle), 1 nM E2, or 1 nM P4, 
MPA, NET or DRSP in the absence and presence of 1 nM E2 for 2 hours followed by re-ChIP assays. 
(A) Schematic representations of cis-elements in the promoter regions of CCND1 and MYC (adapted 
from [34]), and the primer positions. Cell lysates were subjected to immunoprecipitation (IP) with an 
anti-IgG antibody (negative control) or a PR-A/PR-B-specific antibody followed by an ERα-specific 
antibody, and vice versa, prior to real-time qPCR analysis of the resulting immunoprecipitated DNA 
fragments and input controls. Data shown was normalized to input and IgG controls and expressed as 
the fold response relative to the vehicle control set as one. Results shown are the averages of at least 
two independent experiments. 
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cancer cell proliferation and anchorage-independent growth. However, we know that all of 
these progestogens are potent PR agonists [3,88], while P4 and DRSP are not AR agonists [6], 
and DRSP and NET are not GR agonists [73,78]. P4, although suggested to have partial GR 
agonist activity in some studies and not others [73,78], does not display any agonist activity at 
100 nM [78]. Even though it is likely that the effects of the progestogens on proliferation and 
anchorage-independent growth of the MCF-7 BUS breast cancer cell line are indeed mediated 
by the PR, we cannot exclude a role for the AR or GR in mediating the effects of MPA, or for 
the AR in terms of NET. However, we do show that MPA and NET upregulate the expression 
of the ER-regulated pS2 and/or CTSD genes in the same cell line (Fig. 3A and 3B), by inducing 
an interaction between the PR and ERα (Fig. 5). Moreover, we show the co-recruitment of the 
PR and ERα to the promoters of these genes (Fig. 7). As observed for the proliferation and 
anchorage-independent growth, the effects of MPA and NET on gene expression and the co-
recruitment of the PR and ERα to the promoters of ER target genes was not modulated in the 
presence of E2 (Fig. 3C and 3D). Although P4 and DRSP also induced an interaction between 
the PR and ERα (Supplementary Fig. 1), these progestogens had no effect on pS2 or CTSD 
expression (Fig. 3). Co-recruitment of the PR and ERα to known PR binding sites in the 
CCND1 and MYC promoters in response to P4, MPA, NET and DRSP treatment of the MCF-
7 BUS cell line, under non-estrogenic and estrogenic conditions, was also shown (Fig. 8). The 
observed results in the absence of E2 suggest that the previously reported PR and ERα co-
recruitment to these genes in the T47D cell line in response to MPA treatment [34] is neither 
cell line- nor progestogen-specific.  
Establishing the mechanism behind the increased breast cancer risk associated with estrogen-
progestin HT is a global priority considering that breast cancer is the leading cause of cancer-
related mortality in women in developed countries [89,90]. Furthermore, since estrogen-
progestin HT is associated with higher breast cancer risk than estrogen only HT, and that 
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progestins such as MPA have been implicated in increasing breast cancer risk [8–10,12] while 
other progestins and P4 have not [13–21], molecular studies are required to directly compare 
the effects of progestins relative to each other and P4. Notably, the literature is contradictory as 
to whether progestogens elicit proliferative effects. For example, while some studies provide 
evidence indicating that P4 [91,92] and progestins such as MPA [93,94], NET [93–95], 
gestodene [96–98] and levonorgestrel [95,96,98] increase proliferation in the ER- and PR-
positive MCF-7 and T47D breast cancer cell lines, others show that P4 [91,99–101] and 
progestins such as promegestone (R5020) [91,100,102], MPA [102], NET-A [100] and 
nomegestrol acetate [100] are anti-proliferative in these cell lines [91,99–104]. Some studies 
have even suggested that P4 is proliferative for one cell cycle, after which it exerts anti-
proliferative and pro-apoptotic effects in T47D cells [101,102]. These above-mentioned studies 
and others, suggest that progestogens elicit differential proliferative or anti-proliferative effects 
in different cell lines [94,95,105,106], highlighting the importance of characterizing the 
progestogens in parallel in the same model system. Interestingly, we report similar efficacies, 
but not potencies for proliferation for E2, P4, MPA, NET, and DRSP in the estrogen-responsive 
MCF-7 BUS cell line. For example, the newer-generation progestin DRSP, was 875-fold less 
potent than P4, which most clinical studies have suggested does not increase breast cancer risk 
[10,71]. Remarkably, DRSP was less potent than MPA (37 630-fold) and NET (448-fold), both 
first generation progestins previously associated with increased breast cancer risk [8–10,12]. 
Not only was MPA the most potent progestogen in terms of proliferation of the estrogen-
responsive MCF-7 BUS cell line, but it was also 20-fold more potent than E2. This was 
surprising since this cell line is known to be highly proliferative in response to E2 treatment 
[75]. In light of the above, and since E2 is known to drive breast cancer cell proliferation, our 
results suggest that it is likely that MPA promotes breast cancer development and progression 
to a greater extent than E2, as well as P4, NET and DRSP. However, our results showing that 
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progestogens increased the anchorage-independent growth of the MCF-7 BUS cell line to the 
same extent as each other and E2 (Fig. 1F), suggest that there is no difference in the metastatic 
potential of E2 and the progestogens on breast cancer cells.  
Our results showing that the progestogens increase breast cancer cell proliferation via a 
mechanism requiring both the PR and ER are consistent with previous studies showing a 
similar mechanism for MPA, norgestrel and gestodene [34,96,97]. Moreover, at least one study 
showed a PR and ERα-dependent mechanism for MPA-induced expression of PR regulated 
genes [34]. We next investigated whether these progestogens could regulate the expression of 
two ER-regulated genes, pS2 and CTSD, and whether a similar PR and ERα-dependent 
mechanism is involved. Notably, only MPA significantly increased the mRNA expression of 
both pS2 (Fig. 3A) and CTSD (Fig. 3B), while NET significantly increased the mRNA 
expression of only CTSD (Fig 3B). We then showed that the effects of MPA and NET were 
abrogated when PR and ERα expression was silenced, suggesting that both the PR and ERα 
are required for MPA- and/or NET-induced pS2 and CTSD mRNA expression (Fig. 4). 
However, like others [82], we show that silencing of ERα, also resulted in decreased PR-A and 
PR-B expression (Fig. 4A and 4B), which raised the question as to whether both the PR and 
ER, or only the PR, are required. To exclude the latter, we confirmed that the ER is indeed 
required by showing that the effects on gene expression are abrogated in the presence of the 
ER antagonist, ICI, which reportedly does not affect PR levels [83]. Considering that we have 
previously shown that NET-A, but not MPA, can bind to ERα [6], these results suggest that at 
least the MPA-induced mRNA expression does not occur via a mechanism requiring binding 
to the ER, but rather suggests an indirect role for the ER. 
The concept of crosstalk between the PR and ERα is not novel [35,107,108], however recent 
studies have emphasized that crosstalk between these steroid receptors may play a key role in 
breast cancer etiology [29,34,36,38,39]. These studies revealed that the PR can modulate both 
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the transcriptional activity and chromatin localization of ERα through the formation of PR/ERα 
complexes [29,34,36,39], resulting in a gene expression profile similar to that of PR alone, and 
one that is associated with decreased proliferation and an improved clinical outcome [39]. 
Although Giulianelli and co-workers [34] showed that the PR/ERα complex can be recruited 
to the promoters of PR target genes in response to MPA treatment, and we show similar 
recruitment with P4, NET and DRSP, we are the first to show that the PR and ERα can also be 
co-recruited to the promoter regions of ER target genes in a ligand- and promoter-specific 
manner. This may be due to differences in the conformation of the receptor(s) in response to 
the different progestogens which may result in differential interactions of the ligand-bound 
receptor(s) with specific cis-elements in the pS2 and CTSD promoters. It is known that the pS2 
and CTSD promoters contain different cis-elements [80,86] to which steroid receptors can bind 
[38,109–111]. In addition to the ERE or half-ERE sites to which ERα is known to bind and 
activate transcription [112,113], the promoters also contain activator protein 1 (AP1) sites, via 
which ERα has been shown to increase transcription [109,110]. Specificity protein 1 (Sp1) sites 
are also found in these promoters, and it has previously been shown that the PR increases the 
expression of the PgR [38] and p21 [111] genes via these sites. Interestingly, we have also 
shown that the PR can increase gene expression on a synthetic ERE-containing promoter 
(Supplementary Fig. 2). Furthermore, the PR has previously been shown to interact with an 
ERE/Sp1 site in the PR promoter [38], suggesting that the PR/ERα complex may occupy the 
ERE/Sp1 site in the pS2 and/or CTSD promoters. Further studies are required to delineate the 
precise mechanism whereby the PR/ERα complex mediates the regulation of ER target genes 
by MPA and/or NET. 
 
5. Conclusion 
Collectively, we show that both the PR and ER are required for the P4, MPA, NET and DRSP  
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induced increase in breast cancer cell proliferation and anchorage-independent growth, as well  
as the MPA and/or NET induced upregulation of ER target genes. Moreover, we show that 
PR/ERα complexes are recruited to PR-regulated promoters in response to treatment with P4, 
MPA, NET or DRSP, while recruitment to ER-regulated promoters is ligand- and promoter-
specific. Interestingly, it has previously been suggested that treatment with P4 or the progestin 
R5020, in the presence of E2, induces a PR/ERα complex that causes ERα to be redirected away 
from ER binding sites to mostly PR binding sites that are associated with a good breast cancer 
prognosis [29,39]. Our results, independent of the presence of E2, indicate that progestins 
differentially direct PR/ERα complexes, as P4 and DRSP induce the formation of a PR/ERα 
complex that is recruited only to PR target genes, while the PR/ERα complex induced by MPA 
and NET is recruited to both PR and ER target genes. Although activation of the PR by P4 or 
R5020, in the presence of an estrogen-activated ER complex, has been associated with a more 
favorable outcome [39], one cannot ignore the fact that the PR has previously been shown to 
increase breast cancer progression [114] and that we and others [34] show recruitment of the 
PR/ERα complex to the PR regulated CCDN1 and MYC oncogenes. It is therefore critical that 
the manner in which the PR and ER cooperate to modulate the expression of PR and ER 
regulated genes in response to different progestins is understood. Further studies are thus 
warranted to investigate the clinical relevance of the interaction between the PR and ERα in 
response to progestins in both normal and malignant breast tissue.  
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SUPPLEMENTARY FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Fig. 1. P4 and DRSP induce the formation of a PR/ERα complex. MCF-7 BUS cells 
were incubated with 100 nM E2, P4 or DRSP for 1 hour, after which cell extracts were 
immunoprecipitated (IP) with either an (B) ERα- or a (C) PR-A/B-specific antibody. (A-C) 
Immunoblotting (IB) was performed using antibodies specific for ERα, PR-A/B or GAPDH (internal 
control) and representative blots are shown.  
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Supplementary Fig. 2. Progestogens can activate a simple ERE-driven reporter construct via PR-
A or PR-B. HEK293 cells transfected with 6000 ng pS2-ERE-luciferase promoter-reporter construct 
and 150 ng pGL2basic empty vector, PR-A or PR-B were incubated with EtOH (vehicle control), or 1 
µM R5020, P4, MPA, NET or DRSP for 24 hours. Luciferase activity was measured in relative light 
units and normalized to protein concentration determined using the Bradford method [115]. Results are 
shown as fold luciferase activity where induction with the vehicle control is set as one and all other 
responses set relative to this. Results shown are the averages of two independent experiments. 
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Conclusion and Future Studies 
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5. Concluding discussion 
Estrogens and progestins used in menopausal HT have been associated with increased breast 
cancer risk, with the risk associated with estrogen-progestin combination HT reported to be 
higher than that of estrogen only HT (reviewed in [1]). However, the latter was shown for 
isolated progestins and considering the availability of a vast array of progestins with diverse 
structures and functions, risk of breast cancer should not be considered a class effect. 
Interestingly, although some clinical and observational studies indicate that natural P4 may also 
be associated with increased breast cancer risk [1,2], most studies suggest no risk [3,4]. 
Moreover, experimental studies examining the effects of progestins and P4 often report 
contradictory results, emphasizing the variability between different studies and the importance 
of directly comparing hormones used in HT in the same system. Considering the highly-
publicized risks associated with conventional HT, and claims that bioidentical hormones are 
safer, natural alternatives that do not increase breast cancer risk, many women have turned to 
bHT. However, bHT can contain either a single hormone, or a mixture of several hormones, 
and little is known about the molecular mechanism of action of these hormones and whether 
they contribute to breast cancer risk. The primary goal of this study was thus to directly 
compare the transcriptional activities and breast cancer promoting effects of progestins relative 
to natural P4, as well as natural, bioidentical and synthetic estrogens used in HT and bHT. The 
estrogens investigated in this study included the commercially available E2, E3 and E1 standards 
(often used to represent the natural estrogens), custom-compounded bE2 and bE3, and synthetic 
EE, while the progestins included synthetic MPA, NET-A, LNG, GES, NES, NoMAC and 
DRSP. In the first part of this thesis (Chapter 2), the binding affinities and activities of the 
selected estrogens were evaluated in parallel via overexpressed ERα and ERβ in the COS-1 
and HEK293 cell lines. Furthermore, we examined the effects of these estrogens on the 
proliferation and anchorage-independent growth of the estrogen sensitive MCF-7 BUS breast 
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cancer cell line. Since estrogen-progestin combination HT is associated with a greater breast 
cancer risk than estrogen only HT [1], and a conundrum exists on whether progestins can bind 
to the ER subtypes, we also compared the binding of selected progestins relative to each other 
and natural P4 via overexpressed ERα and ERβ in the COS-1 cell line (Chapter 3). Precise 
equilibrium dissociation constants and the estrogenic properties were determined for those 
progestins that could bind. Considering that emerging evidence has highlighted an important 
role for crosstalk between ERα and the PR in breast cancer cell biology [5–8], the final part of 
this thesis (Chapter 4), investigated the role of interplay between the PR and ERα in mediating 
progestogen-induced gene expression, proliferation and anchorage-independent growth of the 
MCF-7 BUS cell line under both non-estrogenic and estrogenic conditions. 
 
5.1. Comparing the estrogenic properties of natural, synthetic and custom-compounded 
bioidentical estrogens via ERα and ERβ 
In the first part of Chapter 2, precise Kd/Ki values of the estrogens for ERα and ERβ were 
determined in the COS-1 cell line using competitive whole cell binding assays. Although a 
number of studies have previously examined the binding of natural and synthetic estrogens to 
the ER, these studies seldom used human ER, often failed to differentiate between the ER 
subtypes [9–13] and usually reported EC50 values or relative binding affinities (RBAs) [9–14] 
rather than accurate Kd/Ki values. This is important as Kd/Ki values remain constant between 
experimental systems, while EC50/RBA values do not [15]. Collectively, our results showed 
that although all the estrogens investigated in this study mostly displayed similar binding 
affinities to E2 for ERα and ERβ, they had higher affinities for ERα than ERβ. The bioidentical 
estrogens bind to both ER subtypes with similar affinities to their natural counterparts, while 
EE had a higher affinity than E2 and the bioidentical estrogens for ERα, but a similar affinity 
for ERβ. 
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We also compared the effects of the estrogens on transactivation and transrepression of gene 
expression via overexpressed ERα or ERβ. For transactivation, we transfected a synthetic ERE-
containing promoter-reporter construct into the HEK293 cell line, but also examined effects on 
an endogenous ERE-containing gene in the MCF-7 BUS cell line endogenously expressing 
both ER subtypes. The MCF-7 BUS cell line, also termed MCF-7 BOS, was cloned from the 
well-studied MCF-7 cell line and used as it is highly responsive to estrogens [16]. COS-1 cells 
were used for competitive whole cell binding assays, while the HEK293 cell line was used for 
all promoter-reporter assays as we were unable to optimize transrepression assays in COS-1 
cells. We showed that although all the estrogens investigated were full ERα and ERβ agonists 
on the synthetic ERE-containing promoter, E1, E3 and EE were less potent than E2 via ERα, 
and only E1 was less potent via ERβ. Furthermore, although no differences were observed in 
the efficacies of the estrogens for ERα versus ERβ, most estrogens displayed higher potencies 
via ERα, except E3 and bE3. In terms of the regulation of an endogenous ERE-containing gene, 
the pS2 gene was selected as it is a well-known marker of breast cancer that is upregulated in 
ER positive tumors [17], and frequently used to assess the regulation of ER-target genes [18–
25]. Notably, bE2, E3, bE3 and EE were as efficacious and potent as E2 in upregulating pS2 
mRNA expression, while E1 was the least efficacious and potent. The result showing that E3 is 
a full ER agonist is contrary to previous claims that E3 is a weak estrogen [26–29], but in line 
with at least one study showing that E3 elicits similar transcriptional effects to E2 on both 
synthetic and endogenous ERE-containing promoters [30].  
Although transrepression of gene expression is a well-accepted mechanism of steroid receptor 
action, few studies have characterized the ERα- and ERβ-mediated transrepression induced by 
estrogens. Our study is the first to directly compare the efficacies and potencies of custom-
compounded bioidentical estrogens relative to the commercial estrogen standards and synthetic 
EE for transrepression via overexpressed ERα and ERβ in HEK293 cells, and on the 
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endogenous NFκB containing IL-6 gene in MCF-7 BUS cells. IL-6 is a pro-inflammatory 
cytokine that contributes towards breast cancer disease progression and is a marker of poor 
prognosis in ERα positive breast cancer tumors [31,32]. For promoter reporter assays, we 
transfected a p(IL6κB)350hu.IL6P-luciferase construct containing three copies of the NFκB 
binding site into HEK293 cells, as no E2-induced repression was observed in COS-1 cells 
transfected with this construct, or in the COS-1 and HEK293 cell lines transfected with a 
5xNFκB-luciferase construct containing five copies of the NFκB binding site (Addendum 1, 
Fig A6). These findings show that the ability of ERα to repress NFκB activity is both cell line- 
and promoter-specific, suggesting that the transrepression mechanism is complex. For the 
estrogens used in this study, we showed for the first time that they were all full ER agonists for 
transrepression, but displayed differential potencies. E1 was more potent than E2 via ERα on 
the synthetic promoter, while EE was more potent via ERβ. On the endogenous IL-6 promoter 
in the MCF-7 BUS cell line expressing both ER subtypes, E3, bE3 and EE were less potent than 
E2. Considering that all the estrogens used in this study repressed gene expression at 
concentrations reflecting serum concentrations in women using HT, it is likely that these 
estrogens may similarly repress the expression of pro-inflammatory genes in vivo. 
Understanding the physiological implications of repression of pro-inflammatory genes such as 
IL-6 in breast cancer is not straightforward. Considering that IL-6 contributes towards breast 
cancer disease progression, possibly due to its role in promoting inflammation [33,34] and 
resisting apoptosis [31,32], repression of IL-6 expression is a potential mechanism whereby 
estrogens may in fact protect against breast cancer. Indeed, follow up studies to the WHI 
clinical trial investigating the risks associated with the use of conjugated equine estrogens 
(CEE) alone, reported a decrease in breast cancer risk [35]. However, our results suggesting 
protection against breast cancer by the inhibition of a pro-inflammatory cytokine gene but 
promotion of breast cancer by the upregulation of an ER target gene, emphasize that the role 
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of estrogens in breast cancer is complex and dependent on numerous factors, including a 
balance between transactivation and transrepression of gene expression.  
Since proliferation and anchorage-independent growth are phenotypic responses that represent 
an integrated model to which both transactivation and transrepression contribute [36–38], we 
next compared the effects of the estrogens on these hallmarks of breast cancer in the MCF-7 
BUS cell line. The results for proliferation indicated a similar trend to transactivation via ERα, 
suggesting that the proliferative effects of the estrogens may predominantly be ERα-mediated. 
This is not surprising since ERα is known to drive breast cancer cell proliferation [39–49]. 
Moreover, results from anchorage-independent growth assays suggested that all the estrogens 
investigated in this study may similarly increase breast cancer metastasis, as they all increased 
the anchorage-independent growth of MCF-7 BUS cells to a similar extent.  
According to proponents of bHT, there are two main justifications for the use of E3 and/or E1 
in biest or triest formulations in bHT; firstly that E1 and E3 are weak estrogens [26–29,50] and 
secondly that E3 can antagonize the activity of E2 [28,50–54]. For example, a study using a 
cell-free transcription assay has previously showed that E3 is a weaker estrogen than E2, and 
that 500 nM or 1 µM E3 could antagonize the effects of 100 nM E2 [50]. Our results at 
physiological concentrations of E1 and E3 showed that these were not weak estrogens in our 
model systems, and thus it was not surprising that we showed that neither estrogen could 
antagonize E2-induced gene expression, cell proliferation or anchorage-independent growth. 
Consistent with our result for E3, Diller and co-workers [30] have previously shown that E3 
elicits similar effects to E2 on gene expression and proliferation of the MCF-7 and T47D breast 
cancer cell lines. Furthermore, we showed that the lack of antagonist effects of E1 and E3 on 
gene expression was not promoter-specific, as similar effects on the pS2 and IL-6 genes were 
shown on the CTSD and RANTES genes. CTSD is frequently used as a marker of ER-regulated 
gene expression [7,21,55,56] and its overexpression in breast tumors has been linked to 
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processes such as metastasis and invasion [57]. RANTES on the other hand, is a pro-
inflammatory chemoattractant known to regulate breast cancer tumor progression [58].  
Taken together, we show that the custom-compounded bioidentical estrogens mimic their 
respective commercial estrogen standards and often also mimic synthetic EE in terms of 
binding affinity, gene expression, breast cancer cell proliferation and anchorage-independent 
growth. Overall these findings suggest that the custom-compounded estrogens, commercially 
available estrogens and synthetic EE have similar effects on breast cancer risk, indicating no 
clear advantage in choosing bHT instead of conventional HT. 
 
5.2. Comparing the estrogenic properties of progestins used in HT via ERα and ERβ 
In the publication constituting Chapter 3 of this thesis, the androgenic and estrogenic properties 
of selected progestogens were evaluated. As only the characterization of the estrogenic 
properties of the progestogens were an aim of this thesis, the androgenic properties will not be 
discussed here. Although some studies have previously shown that progestins such as MPA 
and NET can bind to the ER and elicit estrogenic activity, others have indicated that they cannot 
bind to the ER (reviewed in [59]), or that progestin metabolites, rather than parent progestins, 
may bind [60,61]. These contradictory findings may be due to differences in model systems 
used, as some cell lines endogenously express a number of steroid receptors to which progestins 
may bind [62,63]. These discrepancies, in addition to the fact that studies frequently fail to 
distinguish between the ER subtypes [64,65], may also result in the reporting of inaccurate 
results. For this study, we thus used the COS-1 and HEK293 cell lines as in Chapter 2, to 
comparatively evaluate the binding and activity of selected progestins from different 
generations, relative to each other and P4, via the individual ER subtypes. Both these cell lines 
are frequently used for characterization studies as they lack the expression of significant levels 
of endogenous steroid receptors [66,67]. Our results revealed that only NET-A, LNG and GES, 
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progestins structurally derived from the estrogen precursor testosterone, bind to human ERα. 
We are the first to report accurate Ki values of these progestins for ERα and showed that none 
of the progestins or natural P4 could bind to human ERβ.  
Similar to the characterization of the estrogens in Chapter 2, we next determined the efficacies 
and potencies of NET-A, LNG and GES for ERα-mediated transactivation and transrepression 
of gene expression. Our results showed that while LNG and GES displayed full ERα agonist 
activity for transactivation, and NET-A partial agonist activity, these progestins displayed 
lower potencies than E2. We are the first to evaluate ERα-mediated repression of gene 
expression by progestins and show that while NET-A and GES displayed full agonist activity 
for transrepression, and LNG partial agonist activity, NET-A and LNG were less potent than 
GES. As previous studies have suggested that progestin metabolites rather than the parent 
progestins bind to the ER and elicit estrogenic effects, we cannot exclude that the results 
observed in our study may be due to progestin metabolites. However, it is likely that the 
progestins are not metabolized in our model cell lines considering that NET-A, LNG and GES 
metabolites have previously been shown to bind to and transactivate gene expression via ERβ 
[60,61], while we do not observe binding to ERβ in COS-1 cells, or ERβ-mediated 
transactivation or transrepression in HEK293 cells.  
To understand the possible physiological implications of our results, one should consider that 
NET-A, LNG and GES have approximately a 16-, 1021- and 119-fold lower affinity for ERα 
than E2, respectively, and that the EC50 values of the progestins for transactivation and 
transrepression are lower than the serum concentrations of these progestins in women using 
endocrine therapies. It is thus unlikely that NET-A, LNG or GES will compete with E2 for 
binding to ERα in target tissues. Although it is unlikely that the progestins will bind to and 
elicit ERα-mediated effects in vivo, our study provides clarity regarding the activity of selected 
Stellenbosch University  https://scholar.sun.ac.za
  
152 
 
progestins from different generations via individual ER subtypes. Lastly, these findings 
underline the fact that not all progestins elicit similar activity at the molecular level and 
emphasize that the current grouping of the effects of progestins as a class should be avoided. 
 
5.3. Comparing the effects and underlying mechanisms of selected progestins on ER 
target gene expression and hallmarks of breast cancer 
Considering that some progestins have been associated with increased breast cancer risk while 
natural P4 and dydrogesterone (a P4 isomer) have not [68], in Chapter 4 we compared the effects 
of selected progestins relative to P4 on gene expression, breast cancer cell proliferation and 
anchorage-independent growth in the estrogen-sensitive MCF-7 BUS breast cancer cell line. 
Moreover, we performed a detailed investigation into the underlying mechanisms of these 
effects. We showed that P4, MPA, NET and DRSP had similar efficacies, but not potencies for 
proliferation, supporting the concept that individual progestins do not have the same effects on 
breast cancer risk. More specifically, P4 and NET displayed similar potencies to each other and 
E2, while MPA was the most potent and DRSP the least potent. Considering that MPA has been 
linked to increased breast cancer risk in multiple clinical trials [1,3,69,70], it was not surprising 
that this first-generation progestin was the most potent. However, the fact that P4 displayed a 
similar potency to E2 was surprising since E2 is known to drive breast cancer (reviewed in 
[71,72]), while clinical and observational studies have mostly suggested that P4 does not 
increase breast cancer risk [3,4]. Furthermore, some studies have reported an association 
between NET-A and breast cancer, while others have not [73,74]. Our results showing that 
NET-A displayed a similar potency to E2 suggest that NET-A may indeed increase breast 
cancer risk. The serum concentrations of DRSP (5.0 - 12.4 nM), MPA (1.8 - 12.4 nM) and 
NET-A (1.1 - 31.4 nM) are similar in women using HT [75–79], yet we showed that the potency 
of DRSP for proliferation was significantly less than MPA and NET-A, suggesting that DRSP 
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may promote proliferation to a lesser extent than progestins such as MPA and NET-A in vivo. 
Moreover, we showed that the progestins promoted proliferation both in the absence and 
presence of E2, which is contrary to the proposed idea that progestins promote proliferation in 
the absence of E2, while antagonizing proliferation in the presence of E2 (reviewed in [80]). 
Similarly, we also showed that the presence of E2 did not affect the progestogen-induced 
increase in the anchorage-independent growth of the MCF-7 BUS cell line.  
Initial experiments blocking progestogen-induced proliferation and anchorage-independent 
growth with ICI or RU486 indicated that the ER, and possibly the PR, are involved in mediating 
these effects. The result showing the requirement of the ER for MPA-induced effects on 
proliferation is consistent with a previous study indicating that ICI inhibited MPA-induced 
proliferation [6,81]. Although RU486 is not a PR-specific antagonist, a role for the PR in 
mediating at least the effects of MPA and NET was confirmed at the level of gene expression 
using siRNA targeting the PR. Support for a role of both the ER and PR are gained from studies 
showing that MPA and R5020 inhibited proliferation in MDA-MB-231 cells expressing only 
the PR [82], while they promoted proliferation in cell lines expressing both the PR and ERα 
[81,83]. Interestingly, our Co-IP results showed an association between the unliganded PR and 
ERα in the MCF-7 BUS cell line, and an increased interaction in response to P4, MPA, NET 
and DRSP treatment. Similar results have previously been shown for P4 in MCF-7 cells [5] and 
for P4 and MPA in T47D cells [5,6]. Considering that the observed progestogen-induced breast 
cancer cell proliferation and anchorage-independent growth required the ER and PR, we next 
investigated whether the selected progestins and P4 could modulate the mRNA expression of 
the ERE-containing ER-regulated pS2 and CTSD genes previously used in Chapter 2. 
Remarkably, only MPA increased pS2 mRNA expression, while both MPA and NET-A 
increased the mRNA expression of CTSD, suggesting ligand- and promoter-specific regulation 
by these progestins. Here, we also showed that both the PR and ER were required for the effects 
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of MPA and NET on pS2 and/or CTSD expression, as these effects were abrogated in the 
presence of the ER antagonist ICI, and upon PR and ERα knockdown. Although the activated 
PR traditionally binds to PREs, in this chapter we have shown that both PR-A and PR-B can 
activate gene expression via a synthetic ERE in the presence of P4, R5020, MPA, NET and 
DRSP.  
In Chapter 3, we showed that NET-A, but not MPA, binds to ERα, thus it is evident that effects 
induced by MPA occur via a mechanism that does not require direct binding of MPA to ERα, 
while effects of NET may be partly mediated by ERα. Interestingly, a similar requirement for 
both the PR and ERα had previously been shown for the effects of MPA on the regulation of 
PRE-containing PR target genes. Specifically, co-recruitment of the PR and ERα to the 
promoter regions of CCND1 and MYC PR target genes were shown [6]. Although we did not 
compare the effects of the progestogens on the expression of the CCND1 and MYC genes, we 
also showed recruitment of the PR/ERα complex to the promoters of these genes in response 
to P4, MPA, NET and DRSP treatment in the MCF-7 BUS cell line. We showed for the first 
time that this PR/ERα complex is also recruited to the pS2 promoter upon MPA treatment and 
to the CTSD promoter upon MPA or NET treatment. Contrary to the idea that progestins elicit 
differential effects in the absence and presence of E2 [80], our study showed that the recruitment 
of the PR/ERα complex to ER and PR target genes in response to selected progestins was not 
modulated by the presence of E2. These findings are in line with our proliferation, anchorage-
independent growth and gene expression results in which the effects elicited by the progestins 
and P4 in the MCF-7 BUS cell line were not influenced by the presence of E2. 
The recruitment of the PR/ERα complex to ER-target genes implicated in breast cancer in 
response to MPA and NET but not P4 or DRSP, suggests that P4 and DRSP may promote breast 
cancer pathogenesis to a lesser extent and thus may be safer options in terms of HT. Although 
it has recently been proposed that the redirection of activated ERα in the presence of a PR 
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ligand, whether an agonist or antagonist, results in the activation of genes associated with an 
improved breast cancer outcome (reviewed in [80]), our results showing progestin-specific 
effects in the presence of both unliganded and E2-activated ERα suggests that this may not be 
the case for PR agonists. Moreover, as PR antagonists are known to lead to a different 
conformation of the PR compared to PR agonists [84], it is possible that the antagonist-bound 
PR will elicit differential effects on ER signaling. Further studies to determine the relevance of 
the interaction between the PR and ERα in the clinical setting in both normal and cancerous 
breast tissue are essential, with specific focus on whether PR/ERα crosstalk is linked to good 
or poor prognosis in the presence of different progestins. 
 
5.4. Future studies 
In Chapter 2 of this thesis, we compared the binding affinities and transcriptional activities of 
custom-compounded bE2 and bE3 to that of natural E2, E3, E1 and synthetic EE via 
overexpressed ERα and ERβ in the COS-1 and HEK293 cell lines. In addition, we compared 
the activities of these estrogens on endogenous gene expression, proliferation and anchorage-
independent growth of the MCF7 BUS breast cancer cell line expressing both ERα and ERβ. 
To provide insights into the role of each subtype in mediating the effects observed in the MCF-
7 BUS cells, siRNA targeting ERα or ERβ could be employed. Studies performing 
pharmacological characterizations of the binding affinities and relative efficacies and potencies 
for gene regulation of progestins from different generations via individual steroid receptors are 
lacking. Chapter 3 of this thesis has subsequently addressed this paucity of knowledge for ERα 
and ERβ. However, a limitation of this study is that we did not investigate the influence of the 
ERα-mediated effects of NET-A, LNG and GES on any endogenous ERE- or NFκB-containing 
promoters. Considering that we demonstrated promoter-specific regulation of ER-target genes 
by NET in Chapter 4, the effects of NET-A, LNG and GES should be further pharmacologically 
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characterized on several endogenous genes such as PgR, CTSD, IL-6 and RANTES. Although 
we, and a collaborator, have performed thorough pharmacological characterizations of several 
progestins for the AR [66,85], and of MPA and NET-A for the GR and MR [86–88], it would 
also be interesting to conduct similar experiments for other progestins used in HT via the GR, 
MR and PR isoforms. This is important given the link between progestins and increased breast 
cancer risk, and the prominent role of all steroid receptors in breast cancer biology. To provide 
insight into the role of specific steroid receptors in mediating the effects of specific progestins 
in breast cancer, it would be interesting to perform experiments investigating the effects of 
progestins on the various hallmarks of breast cancer in the absence and presence of steroid 
receptor-selective antagonists and steroid receptor-specific knockdown or overexpression. This 
is critical as understanding the molecular mechanism of action of progestins via specific steroid 
receptors may lead to the identification of novel breast cancer therapies.  
Considering that many progestins are known to undergo metabolism [61], and it has been 
suggested that some metabolites rather than the parent compound bind to and activate the ER 
subtypes [60,61], discriminating between the binding of the parent compound versus its 
metabolites is not an easy task. However, as a first step, it would be interesting to investigate 
the metabolism of various progestins in different cell line and tissue models. Work in this 
regard using ultra-performance liquid chromatography/tandem mass spectrometry analysis has 
already begun in our laboratory and that of our collaborator.   
An association between the PR and ERα was first reported more than ten years ago [89,90], 
but recent studies have highlighted a critical role for the interplay between these two receptors 
in breast cancer biology. The evidence indicates that ERα and the PR are co-recruited to the 
promoters of PR-regulated oncogenes in response to MPA [6], while a genome-wide study 
showed that treatment with P4 and R5020 resulted in the PR modulating ER target gene activity 
by redirecting activated ERα to genes associated with good prognosis [5]. Indeed, in Chapter 
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4 we have shown that P4, MPA, NET and DRSP also lead to the recruitment of a PR/ERα 
complex to the promoters of the CCND1 and MYC PR target genes. However, we also showed 
that only MPA and/or NET could cause the upregulation of ER target genes via co-recruitment 
of the PR and ERα to the pS2 and CTSD promoters. Our results showing ligand and promoter-
specific effects for the progestins used in this study (Chapter 4) are consistent with evidence in 
the literature indicating ligand-, promoter- and cell line-specific effects of progestins 
[86,87,91,92]. To exclude the possibility of cell line-specific effects, gene expression, ChIP 
and re-ChIP assays should be repeated in at least one other breast cancer cell line such as the 
ER- and PR-positive T47D cells. The above-mentioned progestin-specific effects reiterate the 
importance of investigating effects of individual progestins, rather than drawing conclusions 
for all progestins based on studies using isolated progestins or natural P4. Thus, genome-wide 
studies using ChIP-seq analysis should be performed to investigate the binding of the PR/ERα 
complex in the presence of different progestins, under both non-estrogenic and estrogenic 
conditions. 
Further experiments are required to gain insight into the precise mechanism whereby PR and 
ERα may be regulating the expression of the pS2 and CTSD genes. Although we proposed that 
PR and/or ERα may be interacting with the ERE in these gene promoters, our ChIP primers 
were not specific to the ERE region but included other cis-elements such as Sp1, AP1 and AP2 
to which these receptors may bind. For example, it is known that the PR can increase the 
expression of the PgR [93] and p21 [94] genes by interacting with the Sp1 sites in the promoters 
of these genes. Similarly, it has previously been shown that two Sp1 sites in the promoter of 
the PgR gene are required for E2-activation of this gene via ERα [95,96]. To identify specific 
cis-elements involved, primers that are more specific to the promoter region containing only 
the ERE could be designed. However, considering the close proximity of the cis-elements in 
the promoters, this may not be possible. In this instance, ChIP and re-ChIP assays could be 
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conducted in the presence of siRNA targeting transcription factors such as AP1 or Sp1 to 
exclude the tethering of the PR/ERα complex to transcription factors bound to these cis-
elements in the promoters of ER target genes. Interestingly, the DBDs of the ER [97] and AR 
[98] have previously been mutated so as to characterize the binding of these receptors to 
hormone response elements. It may thus be interesting to perform similar experiments for ERα 
and the PR to determine whether one or both receptors are directly interacting with a specific 
response element in the promoters of target genes.  
Despite the above-mentioned studies all investigating the role of ERα in breast cancer biology, 
it is well-known that the ERβ subtype also plays a role in breast cancer. Evidence in the 
literature indicates that ERβ can inhibit ERα-driven proliferation in ER-positive breast cancer, 
while promoting proliferation in the absence of ERα [39–44,46–49,99]. To the best of our 
knowledge, no studies have investigated the possibility of an association between ERβ and the 
PR in breast cancer. Our attempts at investigating such as interaction have been unsuccessful 
due to lack of a suitable commercial ERβ antibody. Indeed, a recent comparison of commonly 
used commercial ERβ antibodies, including one of the antibodies we tested (Santa Cruz 
Biotechnology; sc8974), reported limitations in antibody specificity [100]. Similarly, since PR 
antibodies, including the one used in this study, tend to detect both PR-A and PR-B, further 
studies are required to determine whether PR-A and PR-B play distinct roles in PR/ER 
crosstalk. To determine whether the ER subtypes preferentially form heterodimers with a 
specific PR isoform, and whether this is influenced by receptor levels or the presence of 
different progestins, could be investigated using three-color spectral Förster resonance energy 
transfer (3sFRET) microscopy [101]. This technique would entail the labeling of PR-A and 
PR-B with distinguishable fluorophores that could both be excited by the emission spectrum 
of a third fluorophore tagged to ERα or ERβ, thus allowing the determination of whether ERα 
or ERβ preferentially binds a specific PR isoform.  
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Similar to our results showing that MPA was the most, and DRSP the least potent in terms of 
proliferation, a previous study has reported a similar trend for the promotion of breast cancer 
cell migration and invasion [102]. It would thus be interesting to directly compare the effects 
of different progestins on migration and invasion, as well as other hallmarks of cancer such as 
apoptosis. Finally, it would be beneficial to examine the oncogenic effects of different 
progestins relative to natural P4, on breast tumor explants since these tissues represent a more 
physiological model system and have previously been used to validate findings from cell line 
experiments [5,8]. 
 
5.5. Conclusion 
Taken together, the results presented in this thesis show that custom-compounded bE2 and bE3 
mimic their respective commercially available natural estrogen standards and synthetic EE, 
suggesting that bHT is not necessarily a safer alternative to conventional HT. Furthermore, the 
fact that similar maximal responses were observed for these estrogens in terms of gene 
expression and breast cancer cell proliferation at concentrations reflecting serum estrogen 
levels, highlights the potential of these estrogens to display similar effects in vivo. Moreover, 
our results show that E3 and E1 are not weak estrogens, and that they do not antagonize the 
activity of E2. This finding implies that the rationale behind using E3 and E1 in custom-
compounded biest and triest bHT formulations should be re-evaluated.  
The results investigating the binding and activity of selected progestins from different 
generations via overexpressed ERα or ERβ in COS-1 and HEK293 cells show that NET-A, 
LNG and GES bind only to ERα and display differential agonist activity. Considering the 
potencies of these progestins for gene regulation however, and their reported serum 
concentrations relative to that of E2, our results suggest that the progestins would not elicit 
estrogenic effects in vivo. We do, however, show that MPA, NET-A, DRSP and P4 may 
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contribute to breast cancer progression by stimulating breast cancer cell proliferation and 
anchorage-independent growth via a mechanism requiring the ER and PR, with DRSP being 
the least potent and MPA the most. This suggests that the fourth-generation progestin DRSP 
may be a safer conventional HT option than MPA and NET in terms of breast cancer risk. 
Moreover, the result showing that P4, MPA, NET and DRSP all induced the co-recruitment of 
ERα and the PR to the promoters of known PR-regulated oncogenes, while only MPA and NET 
caused co-recruitment to the promoters of ER target genes, suggests that progestins such as 
MPA and NET may promote breast cancer pathogenesis by regulating both PR and ER target 
genes. Overall, the results of this thesis add to the understanding of estrogens and progestogens 
used in menopausal hormone therapies and highlight the concept that all progestins used in 
conventional HT are not equal. Finally, this study contributes to the knowledge and 
understanding of the physiological responses elicited by estrogens and progestins, while 
providing the potential underlying mechanisms.  
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A1. Increasing the ratio of the PR isoforms relative to the ER subtypes increases the 
efficacy of both ERα and ERβ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A1. Unliganded PR-A and PR-B differentially modulate the transcriptional activity of 
ERα and ERβ. HEK293 cells expressing the pS2-ERE-luciferase promoter-reporter construct, (A) ERα 
or (B) ERβ, and increasing concentrations of either PR-A or PR-B was incubated with increasing 
concentrations of E2 for 24 hours. Luciferase activity was measured in relative light units and 
normalized to protein concentration. Results are shown as relative luciferase activity where induction 
via ERα or ERβ only at 10-7 M E2 was set as 100% and all other responses set relative to this. Maximal 
response and EC50 values are reported in Table A1. Results shown are representatives of at least three 
independent experiments. 
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A2. The PR isoforms increase the transcriptional activity of ERα in a progestin-specific 
manner 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A2. Ligand activated PR-A and PR-B increase the efficacy and potency of ERα. HEK293 
cells expressing ERα and the pS2-ERE-luciferase promoter-reporter construct in the absence and 
presence of increasing concentrations of (A-C) PR-A or (D-F) PR-B, were treated with increasing 
concentrations of E2 in the absence and presence of 1 µM R5020 (■), P4 (▲), MPA (▼), NET (⁕) or 
DRSP (○) for 24 hours. Luciferase activity was measured in relative light units and normalized to 
protein concentration. Results are shown as relative luciferase activity where induction via ERα only at 
10-7 M E2 was set as 100% and all other responses set relative to this. Maximal response and EC50 values 
are reported in Table A1. Results shown are representatives of at least three independent experiments. 
A D ERα + PR-A (1:1) ERα + PR-B (1:1) 
B E ERα + PR-A (1:2) ERα + PR-B (1:2) 
C F ERα + PR-A (1:10) ERα + PR-B (1:10) 
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A3. The progestin-bound PR isoforms differentially increase the transcriptional activity 
of ERβ  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A3. Ligand activated PR-A and PR-B increase the efficacy and potency of ERβ. HEK293 
cells expressing ERβ and the pS2-ERE-luciferase promoter-reporter construct in the absence and 
presence of increasing concentrations of (A-C) PR-A or (D-F) PR-B were treated with increasing 
concentrations of E2 in the absence and presence of 1 µM R5020 (■), P4 (▲), MPA (▼), NET (⁕) or 
DRSP (○) for 24 hours. Luciferase activity was measured in relative light units and normalized to 
protein concentration. Results are shown as relative luciferase activity where induction via ERβ only at 
10-7 M E2 was set as 100% and all other responses set relative to this. Maximal response and EC50 values 
are reported in Table A1. Results shown are representatives of at least three independent experiments.  
A D ERβ + PR-A (1:1) ERβ + PR-B (1:1) 
B E ERβ + PR-A (1:2) ERβ + PR-B (1:2) 
C F ERβ + PR-A (1:10) ERβ + PR-B (1:10) 
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A4. The unliganded and progestin-activated PR isoforms differentially increase the 
transcriptional efficacy and potency of ERα and ERβ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A4. Progestogen-activated PR-A or PR-B differentially modulate the transcriptional 
activity of ERα and ERβ. Dose response curves (Figures A1-A3) and non-linear regression analysis 
were used to determine (A) maximal response and (B) EC50 values. The relative values are reported in 
Table A1 and are visually represented here using heat maps. 
A 
B 
Maximal Responses 
EC50 values 
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Table A1. Relative agonist efficacies and potencies of E2 for transactivation via the ER on a synthetic ERE-containing promoter-reporter construct 
in the absence and presence of increasing concentrations of unliganded or progestogen-bound PR-A or PR-B. 
Maximal Response ± SEM (ERα only = 100 ± 0 %) 
Ratio Vehicle R5020 P4 MPA NET DRSP 
ERα + PR-A 
1:1 144.8 ± 35.0 105.6 ± 0.5 117.8 ± 72.1 148.4 ± 15.2 154.7 ± 11.0 106.3 ± 2.1 
1:2 182.9 ± 34.0 216.6 ± 19.5 164.8 ± 15.9 126.5 ± 19.9 168.4 ± 2.7 178.2 ± 45.6 
1:10 269.4 ± 38.9 129.7 ± 10.2 132 ± 20.8 130.6 ± 3.2 118.2 ± 0.1 185.4 ± 65.6 
ERα + PR-B 
1:1 241.5 ± 42.0 484.4 ± 91.4 680.4 ± 183.4 724.6 ± 167.3 466.1 ± 114.2 294.7 ± 32.14 
1:2 326.0 ± 70.7 548.6 ± 130.5 512.6 ± 120.1 592.3 ± 9.6 484.9 ± 69.5 478.5 ± 184.2 
1:10 328.4 ± 34.2 420.4 ± 105.6 334.9 ± 82.9 331.2 ± 66.8 399.5 ± 55.6 414.9 ± 121.9 
EC50 ± SEM (ERα only = 3.9 ± 1.8 pM) 
Ratio Vehicle R5020 P4 MPA NET DRSP 
ERα + PR-A 
1:1 4.3 ± 1.1 0.3 ± 0.06 0.06 ± 0.004 0.4 ± 0.1 0.4 ± 0.2 1.8 ± 0.07 
1:2 3.6 ± 0.6 0.3 ± 0.1 0.4 ± 0.3 0.5 ± 0.2 0.2 ± 0.1 0.2 ± 0.04 
1:10 6.7 ± 1.4 0.4 ± 0.2 0.6 ± 0.1 0.7 ± 0.6 0.4 ± 0.2 0.06 ± 0.01 
ERα + PR-B 
1:1 2.4 ± 0.6 0.02 ± 0.001 0.2 ± 0.03 0.02 ± 0.008 0.8 ± 0.5 0.3 ± 0.08 
1:2 0.4 ± 0.1 0.6 ± 0.1 0.3 ± 0.1 0.5 ± 0.2 0.2 ± 0.08 0.06 ± 0.02 
1:10 0.5 ± 0.4 0.4 ± 0.2 0.2 ± 0.01 0.04 ± 0.02 0.3 ± 0.1 0.08 ± 0.007 
Maximal Response ± SEM (ERβ only = 100 ± 0 %) 
Ratio Vehicle R5020 P4 MPA NET DRSP 
ERβ + PR-A 
1:1 187 ± 20 230 ± 8.4 280 ± 55 380 ± 69 340 ± 70 230 ± 78 
1:2 130 ± 0.08 220 ± 36 250 ± 76 360 ± 58 280 ± 110 230 ± 11 
1:10 250 ± 100 240 ± 70 350 ± 150 310 ± 80 310 ± 100 270 ± 45 
ERβ + PR-B 
1:1 150 ± 27 210 ± 9.7 230 ± 43 360 ± 53 220 ± 37 250 ± 49 
1:2 210 ± 57 320 ± 72 280 ± 70 320 ± 60 300 ± 78 330 ± 71 
1:10 240 ± 15 450 ± 150 460 ± 140 440 ± 65 510 ± 120 450 ± 78 
EC50 ± SEM (ERβ only = 51.1 ± 13.4 pM) 
Ratio Vehicle R5020 P4 MPA NET DRSP 
ERβ + PR-A 
1:1 0.9 ± 0.8 5.7 ± 5.3 0.7 ± 0.6 1.4 ± 0.3 1.4 ± 1.4 0.3 ± 0.1 
1:2 0.7 ± 0.003 2.1 ± 1.0 9.0 ± 0.7 7.2 ± 2.0 0.7 ± 0.5 2.3 ± 1.6 
1:10 0.8 ± 0.04 0.3 ± 0.1 2.5 ± 2.0 1.2 ± 0.4 0.2 ± 0.07 6.7 ± 2.2 
ERβ + PR-B 
1:1 38 ± 22 35 ± 12 30 ± 20 18 ± 8.3 1.8 ± 0.5 0.5 ± 0.2 
1:2 62 ± 19 11 ± 4.1 51 ± 36 26 ± 6.5 31 ± 6.4 1.1 ± 0.6 
1:10 18 ± 14 1.4 ± 0.8 1.0 ± 0.7 4.9 ± 4.3 0.2 ± 0.1 0.4 ± 0.2 
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A5. Mycoplasma-negative COS-1, HEK293 and MCF-7 BUS cells  
 
 
 
 
 
 
 
 
 
 
 
Figure A5. Mycoplasma-negative COS-1, HEK293 and MCF-7 BUS cells. All cell lines used in this 
study were routinely tested for mycoplasma infection and only mycoplasma-negative cells were used 
in experiments. (A) COS-1, (B) HEK293 and (C) MCF-7 BUS cells were stained with DNA Hoechst 
33258 dye and visualized using the Olympus IX81 microscope. 
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A6. E2 represses TNFα-induced gene expression via overexpressed ERα or ERβ in a 
promoter-specific manner 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A6. E2 represses TNF-induced gene expression via ERα or ERβ in a promoter-specific 
manner. HEK293 cells expressing the (A, B) 5xNFκB- luciferase- or the (C, D) p(IL6κB)350huIL6P-
luciferase promoter-reporter construct and the (A, C) pSG5-hERα or (B, D) pSG5-hERβ cDNA 
expression vector, were treated with 0.1% EtOH (vehicle control) or 2 ng/ml or 20 ng/ml TNFα in the 
absence or presence of 1 µM E2 for 24 hours. Luciferase activity was measured in relative light units 
and normalized to protein concentration. Results are shown as relative luciferase activity where 
induction with the vehicle control is set as one and all other responses set relative to this. 
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A7. Representative RNA gel showing intact RNA 
 
 
 
 
Figure A7. A representative 1% denaturing agarose gel. RNA was isolated from MCF-7 BUS cells 
using Tri-reagent (Sigma-Aldrich, South Africa) as per the manufacturer’s instructions, and 1 µg of 
each RNA sample was subjected to electrophoresis on a 1% denaturing formaldehyde agarose gel to 
confirm the presence of 28S and 18S subunits in a ratio of approximately 2:1 as an indicator of intact 
RNA. 
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A8. Primer efficiencies of the primer pairs were determined from standard curves 
showing cycle number versus log cDNA concentration 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A8. Representative standard curves that were used to determine primer efficiencies. A 
cDNA dilution series was used to generate standard curves indicating the cycle number versus the log 
concentration of the amplified cDNA. Representative standard curves for (A) pS2, (B) CTSD, (C) IL-
6, (D) RANTES and (E) GAPDH are shown and the reported (F) primer efficiencies (or exponential 
amplification values; E) are the average of two individual experiments performed in triplicate, 
calculated using the equation by Pfaffl (E = 10 [-1/slope]). 
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A9. Melt curve analysis for pS2, CTSD, IL-6, RANTES and GAPDH 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A9. Representative melt curves are shown for pS2, CTSD, IL-6, RANTES and GAPDH. 
Melt curve analysis was conducted for every realtime qPCR experiment to ensure amplicon specificity 
and that the product is not present in the no template control (NTC). Melting curve analysis can be used 
to differentiate between different PCR products, non-specific amplicons as well as primer dimers. 
  
pS2 A CTSD B 
IL-6 C RANTES D 
GAPDH E 
Temperature (°C) 
Temperature (°C) Temperature (°C) 
Temperature (°C) 
Temperature (°C) 
F
lu
o
r
e
sc
e
n
ce
 -
d
(F
1
)/
d
T
 
F
lu
o
r
e
sc
e
n
ce
 -
d
(F
1
)/
d
T
 
F
lu
o
r
e
sc
e
n
ce
 -
d
(F
1
)/
d
T
 
F
lu
o
r
e
sc
e
n
ce
 -
d
(F
1
)/
d
T
 
F
lu
o
r
e
sc
e
n
ce
 -
d
(F
1
)/
d
T
 
NTC NTC 
NTC 
NTC 
NTC 
Stellenbosch University  https://scholar.sun.ac.za
  
181 
 
A10. Representative agarose gel of sonicated chromatin 
 
 
 
 
 
 
Figure A10. An example of an agarose gel indicating sonicated DNA fragments between 200 bp 
and 300 bp in size. A representative agarose gel indicating the size of DNA fragments after sonication 
on 100% power for 60 cycles of 60 seconds each, with 20 second intervals between cycles using the 
Misonix sonicator (Qsonica, RSA). 
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Appendix B 
 
 
Oral and Poster Outputs of the PhD study and 
Contributions to Publications Not Part of This Study 
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Oral and Poster Outputs of the PhD Study 
 
1. Perkins, M., Louw-du Toit, R., Africander, D. Bioidentical hormones used in hormone 
replacement therapy: Implications for breast cancer. SASBMB congress, Goudini Spa 
Resort, South Africa. 6 - 9 July 2014. (Poster Presentation) 
 
2. Perkins, M., Louw- du Toit, R., Africander, D. Investigating the mechanism of action 
of hormones used in hormone replacement therapy via estrogen receptor subtypes and 
influence of the progesterone receptor. FEBS advanced lecture course, Nuclear receptor 
signalling in physiology and disease, Spetses Island, Greece. 23 - 28 August 2015. 
(Oral and Poster Presentation) 
 
3. Perkins, M.S., Louw- du Toit, R., Africander, D. Both the ER and PR are required for 
progestin-induced effects on breast cancer cell proliferation. FASEB Conference, Cell 
Signalling in Cancer: from Mechanisms to Therapy, Snowmass Village, Colorado, 
USA. 5 - 10 June 2016. (Poster Presentation) 
 
4. Perkins, M.S., Louw-du Toit, R., Africander, D. The Rationale Behind Compounded 
Bioidentical Hormone Therapy Should be Reassessed. 25th SASBMB congress, East 
London Convention Centre, East London, South Africa. 10 - 14 July 2016. (Oral 
Presentation) 
 
5. Perkins, M.S., Louw- du Toit, R., Africander, D. Progestin-induced breast cancer: A 
role for estrogen- and progesterone receptor crosstalk. Gordon Research Conference, 
Hormone-dependent Cancers, Sunday River, Newry, Maine, USA. 6 - 11 August 2017. 
(Poster Presentation by Africander, D.) 
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Contributions to publications not part of this study 
 
1. R. Louw-du Toit, M.S. Perkins, J.L. Snoep, K.-H. Storbeck, D. Africander, Fourth-
generation progestins inhibit 3β-hydroxysteroid dehydrogenase type 2 and modulate 
the biosynthesis of endogenous steroids, PLoS One. 11 (2016) e0164170. 
doi:10.1371/journal.pone.0164170. 
For this publication, the candidate was involved with the investigation, formal analysis and 
visualization. The candidate was also involved with reviewing and editing the final publication 
draft. 
 
2. E. Pretorius, D.J. Africander, M. Vlok, M.S. Perkins, J. Quanson, K.-H. Storbeck, 
11-Ketotestosterone and 11-ketodihydrotestosterone in castration resistant prostate 
cancer: Potent androgens which can no longer be ignored, PLoS One. 11 (2016) 
e0159867. doi:10.1371/journal.pone.0159867. 
 
For this publication, the candidate performed the whole cell binding experiments, analyzed the 
data, and wrote the methods section pertaining to these binding experiments. The candidate 
also involved with critical reviewing and editing of the final document. 
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